|
Information For Physicians
Glossary of Terms
Acute Cyanide Poisoning
Acute
cyanide poisoning as a pure toxicity is rare but has been
reported to respond with benefit to hyperbaric oxygen in
some cases. The primary, established therapy is chemical
induction of 30 to 40 percent methemoglobinemia by administration
of amyl nitrite and sodium nitrite with sodium thiosulfate.
Nontoxic cyanomethemoglobin and thiocyanate are formed
when methemoglobin and thiosulfate bind cyanide. Unfortunately,
this treatment itself decreases the oxygen carrying capacity
of the blood, and can cause tissue hypoxia which may require
treatment. The serious nature of the condition warrants
whatever other means may contribute to a more favorable
prognosis (when conventional methods prove inadequate).
In combined carbon monoxide and cyanide smoke inhalation,
oxygen diffusion may be impaired by pulmonary damage and
caroboxyhemoglobinemia may compound the clinical crisis.
In the presence of methemoglobinemia, inadequate tissue oxygenation
is inevitable.
In combined carbon monoxide and cyanide poisoning which may
accompany smoke inhalation, established treatment may have
limited benefit. The physical and physiological rationale
of mass action for hyperbaric oxygen in cyanide poisoning
is very compelling. Results from the animal studies cited
have shown distinct benefit from hyperbaric oxygen in this
toxicity.
Cyanide is one of the most poisonous and
rapidly acting substances known to man, with death occurring
within seconds from a 100 mg inhaled dose and within a few
hours from a 300 mg oral dose. Exposure generally occurs
from smoke inhalation, because cyanide is a common product
of combustion of many organic materials. Less commonly, cyanide
poisoning can occur from occupational contact with the cyanide
used in industrial processes such as electroplating; from
iatrogenic exposure to sodium nitroprusside, a clinical hypotensive
agent; and from suicide attempts. Smoke inhalation carries
the additional co-morbidities of pulmonary injury, thermal
burns, and carbon monoxide poisoning which has a synergistic
toxic effect with cyanide. Cyanide (CN) produces a tissue
hypoxia similar to the more common carbon monoxide (CO) poisoning,
though without binding to hemoglobin. which are less toxic
products.
HBOT provides an alternate pathway to
the transport of oxygen to the tissues by increasing the
serum dissolved oxygen to levels adequate for life, and thereby
bypassing bound hemoglobin. HBOT is also the only treatment
that directly reconstitutes the cytochrome A3 oxidase, and
directly improves functioning of the electron transport system.
References
Birky MM, Clarke FB: Inhalation of toxic products from fires.
Bull NY Acad Med 57:997-1013, 1981.
Burrows GE, Way JL: Cyanide intoxication in sheep: therapeutic
value of oxygen or cobalt. Am J Vet Res 38:223-227, 1977.
\Clark
CJ, Campbell D: Blood carboxyhemoglobin and cyanide levels
in fire survivors. Lancet 1:1332-1335, 1981.
Cope C, Abramowitz S: Respiratory responses to intravenous
sodium cyanide, a function of the oxygen-cyanide relationship.
Am Rev Respir Dis 81:321-329, 1960.
Cope C: The importance
of oxygen in the treatment of cyanide poisoning. JAMA 175:1061-1064.
Cottrell JE, Casthely J: Prevention of nitroprusside induced
cyanide toxicity with hydroxocobalamin. N Engl J Med 298
(15):809-811, 1978.
Fassett DW: Cyanides and nitrites. In Patty FA (ed): Industrial
Hygiene and Toxicology, Vol II. New York: Interscience Publishers,
1963, pp 2455-2456.
Hart GB, Strauss MB: Treatment of smoke
inhalation by hyperbaric oxygen. J Emer Med 3(3):211-215,
1985.
Isom GE, Way JL: Effect of oxygen on cyanide intoxication.
VI. Reactivation of cyanide inhibited glucose metabolism.
J Phar Exp Ther 189:235-243, 1974.
Isom GE, Burrows GE, Way
JL: Effect of oxygen on the antagonism of cyanide intoxication-cytochrome
oxidase, in vivo. Toxicol Appl Pharm 65:250-256, 1982.
Ivanov KP: The effect of elevated
oxygen pressure on animals poisoned with potassium cyanide.
Phar Toxicol 22:476-479, 1959.
Ivankovich AD, Braverman B:
Cyanide antidotes and methods of their administration in
dogs: a comparative study. Anesthesiology 52:210-216, 1980.
Keilin
D: Cytochrome and respiratory enzymes. Proc R Soc Lon (Biol)
104:206-252, 1929.
Kindwall EP: Carbon monoxide and cyanide
poisoning, in: Davis JC, Hunt TK (eds): Hyperbaric Oxygen
Therapy. Bethesda: Undersea Medical Society, 1977, pp 177-190.
Krapez, JR, Vesey CJ: Effects of cyanide antidotes used
with sodium nitroprusside infusions: sodium thiosulfate and
Hydroxocobalamin given prophylactically to dogs. Br J Anesth
53:793-804, 1981.
Litovitz TI, Larin RF, Myers RAM: Cyanide
poisoning treated with hyperbaric oxygen. Am J Emer Med 1:94-101,
1983. Litovitz TL, Larkin RF, Myers RA: Cyanide poisoning
treated with hyperbaric oxygen. Am J Emerg Med 1:94-101,
1983.
Mohler SR: Air crash survival: Injuries and evacuation
toxic hazards. Avia Space Environ Med 46:86-88, 1975.
Myers,
RAM: Cyanide poisoning (acute) in Myers, RAM (ed): Hyperbaric
Oxygen Therapy: A Committee Report, revised. Bethesda: Undersea
and Hyperbaric Medical Society 1986, p 40.
Norris JC, Moore
SJ, Hume AS: Synergistic lethality induced by the combination
of carbon monoxide and cyanide. Toxicology 40: 121-129, 1986.
Sheehy M, Way JL: Effect of oxygen on cyanide intoxication.
III. Mithrodate. J Phar Exp Ther 161:163-168,.
Skene, WG,
Norman JN: Effect of hyperbaric oxygen in cyanide poisoning,
in: Brown IW, Cox B (eds): Proceedings of the Third International
Congress on Hyperbaric Medicine. Washington, D.C.: National
Academy of Sciences-National Research Council, 1966, pp 705-710.
Symington
IS: Cyanide exposures in fires. Lancet 2:91-92, 1978.
Takano
N, Myazaki Y: Effect of hyperbaric oxygen on cyanide intoxication:
in situ changes in intracellular oxidation reduction. Undersea
Biomed Res 7(3):191-197, 1980.
Terrill JB, Montgomery RR:
Toxic gases from fires. Science 200:1343-1347, 1978.
Trapp
WG: Massive cyanide poisoning with recovery: a boxing day
story. Can Med Assn J 120:517, 1970.
Trapp WG, Lepawsky M:
One hundred percent survival in five life threatening cyanide
poisoning victims treated by a therapeutic spectrum including
hyperbaric oxygen. Eighth Annual Conference on Clinical Applications
of Hyperbaric Oxygen. Long Beach: Memorial Hospital Medical
Center, 1983.
Vogel SN, Sultan TR: Cyanide poisoning, Clin
Toxicol 18:367-383, 1981.
Warburg O: Uber die wikung von
kohlenoxyd und stick-oxyd auf atmung und garung. Biochem
Z 189:354-380, 1927. Way JL, Gibbon Sl: Effect of oxygen
on cyanide intoxication. I. Prophylactic protection. J Phar
Exp Ther 153:381-385, 1966.
Wetherell HR: The occurrence of
cyanide in the blood of fire victims. J Forensic Sci 11:167-173,
1966.
Acute
Peripheral Arterial Insufficiency
Acute
peripheral arterial insufficiency covers
a spectrum of disease that includes acute
traumatic and non-traumatic peripheral
arterial insufficiency and acute crush
injuries (with or without compartment syndrome).
Crush or degloving injuries (stripping
of the skin and underlying -tissue from
the bones, usually of the hands or feet as occurs in wringer
or industrial roller injuries) can interrupt large vessels
and the continuity of capillary beds. The edema that follows
often creates a vicious circle, causing complications such
as compartment syndrome (a condition in which pressure within
a confined space results in tissue ischemia and resulting
dysfunction) and frank sloughing of compromised tissue. Large
vessels must be repaired surgically, but the ischemic anoxia
resulting from decreased capillary flow may benefit from
HBOT, which preserves intracellular levels of ATP, reduces
edema, and prevents -reperfusion injury. HBOT also reduces
the tendency of WBCs to adhere to the endothelium of injured
tissue (believed to be important in secondary ischemia).
In a globally hypoxic limb, edema formation can be reduced
by 50% if HBOT is initiated within about 8 hours, providing
that large vessels have not been disrupted.
The first physiologic
effect of hyperbaric oxygen therapy (HBOT) is hyperoxygenation
of the tissues affected by acute arterial insufficiency.
The effect is not linear but logarithmic, and enough oxygen
is physically dissolved in plasma at usual treatment pressures
to raise arterial PO2 by a factor of 10 to 15. Because of
this increase, the oxygen diffusion distance from capillary
to tissue increases three to four times.
Hyperbaric oxygen
also causes a vasoconstriction due to the effect of high
arterial oxygen tensions in chemoreceptors. This 20 percent
reduction in blood flow reduces capillary leakage and diapedesis,
thereby reducing edema. HBOT offers a direct antibacterial
effect on certain anaerobes, and maintains the killing ability
of leukocytes after phagocytosis. HBOT also raises tissue
oxygen tension above the level necessary for fibroblasts
to lay down collagen, for angiogenesis to occur, and for
cellular growth to be supported in healing. Additionally,
HBOT increases the effectiveness of the antibiotics that
require active transport across the cell wall.
Hyperbaric
oxygen theoretically protects tissues from reperfusion injury.
HBOT confers this effect either by maintaining the cell's
ability to produce scavengers that detoxify free radicals
or by preventing lipid peroxidation in cell membranes.
Acute
peripheral arterial insufficiency is defined as the traumatic
or atraumatic reduction of arterial or arteriolar blood flow
to a tissue other than the central nervous system. The mechanisms
of injury can be iatrogenic ("trash foot"),
traumatic damaging of the artery, or vascular occlusion from
a clot or reperfusion injury. The result is acute hypoxia
of the ischemic tissues with cellular death. In an area where
no blood flow exists, tissue death is inevitable; but in
those areas with some perfusion, the use of HBOT maximizes
the oxygen content of the serum phase of the blood and can
save the threatened tissues. HBOT elevates serum PO2 up to
2000 percent. HBOT has been shown to provide sufficient oxygen
delivery to sustain life in a large mammal that has no hematocytes.
The
effectiveness of hyperbaric oxygen in clinical human studies
is well documented, with acute ischemias arising from surgery
and trauma having been particularly well studied. HBOT not
only increases the tissue oxygenation, but through an unknown
mechanism, enables cells to better tolerate ischemia. However,
because HBOT requires adequate circulation to be effective,
documentation of blood flow to the affected area should be
required if this condition is treated with HBOT. The best
currently available technology for indicating the potential
usefulness of HBOT in most ischemic areas is transcutaneous
oxygen monitoring.
A prospective, randomized, placebo-controlled
human study has shown a statistically significant decrease
in the necessity for repeat surgery or amputation with use
of HBOT.
References
Boerema I, Meijne NG, Brummelkamp WH et al.: Life without
blood: a study in the influence of high atmospheric pressure
and hypothermia on dilution of blood. J Cardiovasc Surg 133-146,
1960.
Bowersox JC, Strauss MB, Hart GB: Clinical experiences
with hyperbaric oxygen therapy in the salvage of ischemic
skin grafts and flaps. J Hyperbaric Med. 1:141-149, 1986.
Hill
RK, Bright DE, Neubauer RA: Use of hyperbaric in the reanastomosis
of the severed ear: a review. J Hyberb Med 163-175, 1990.
Hunt
TK, Linsey M, Grislis G, et al.: The effect of varying ambient
oxygen tension on wound infection. Ann Surg 181:35-39, 1975.
Hunt
TK, Pai MP: The effect of varying ambient oxygen tensions
on wound metabolism and collagen synthesis. Surg Gynecol
Obstet 135:561-567, 1972.
Hunt TK: Oxygen and Healing. Am
J Surg 118:521-525, 1969.
Hunt TK, van Winkle W Jr: Wound
healing normal repair, in: Dunphy JE (ed): Fundamentals of
Wound Management in Surgery. South Plainfield: Chirurgecom,
1976, pp 1-68.
Kihara M, McManis PG, Schmelzer JD, et al.:
Experimental ischemic neuropathy: salvage with hyperbaric
oxygenation. Ann Neurol 89-94, 1995.
Nemiroff PM, Merwin
GE, Brant T et al.: HBO and irradiation on experimental skin
flaps in rats. Surg Forum 549-550, 1984.
Nylander G, Lewis
D, Lewis D, Nordström H, Larsson J:
Reduction of postischemic edema with hyperbaric oxygen. Plastic
Reconstr Surg 76:596-601, 1985.
Perrins DJ: The effect of
hyperbaric oxygen on ischemic skin flaps, in: Grabb WC, Myers
MB (eds): Skin Flaps. Boston: Little Brown & Co., 1975,
pp 53-63.
Sheffield PJ: Tissue oxygen measurements with respect
to soft-tissue wound healing with normobaric and hyperbaric
oxygen. Hyperb Oxygen Review 18-46, 1985.
Shupak A, Gozal
D, Ariel A, Melamed Y, Katz A: Hyperbaric oxygenation in
acute peripheral post traumatic ischemia. J Hyperbaric Med
2:7-14, 1987.
Strauss MB, Hargens AR, Gershuni DH, et al.:
Reduction of skeletal muscle necrosis using intermittent
hyperbaric oxygen in a model compartment syndrome. J Bone
Joint Surg 65A:656-662, 1983.
Strauss MB, Hargens AR, Gershuni
DH, Hart GB, Akeson WH: Delayed use of hyperbaric oxygen
for treatment of a model anterior compartment syndrome. J
Orthop Res 4:108-111, 1986.
Strauss MB, Hart GB: Cost-effective
issues in hyperbaric oxygen therapy for complicated fractures.
J Hyperbaric Med 3:199-205, 1988.
Strauss MB, Hart GB: Hyperbaric
oxygen and the skeletal muscle compartment syndrome. Cont
Orthopedics 18:167-174, 1989. Undersea and Hyperbaric Medical
Society: Hyperbaric Oxygen Therapy. A Committee Report. Bethesda:,
UHMS, 1992.
Zamboni WA, Roth AC, Russell RC: Morphologic analysis
of the microcirculation during reperfusion of ischemic skeletal
muscle and the effect of hyperbaric oxygen. Plast and Reconstr
Surg 1110-1123, 1993.
Intravascular Gas Embolism
Air embolism occurs in divers or is secondary to entry of air during vascular
surgery, IV therapy, lung biopsy, pulmonary overinflation during mechanical
ventilation (usually in children), renal dialysis, angiography, etc.
Intravascular gas embolism (IGE) and its subset, arterial gas embolism (AGE),
can occur following exposure to any barometric pressure and may manifest without
compression or decompression from one barometric pressure to another. Even in
normobaric environments, both traumatic and iatrogenic injury can cause IGE/AGE.
Trauma Causing IGE/AGE
1.Penetrating injury to the heart or major vessels.
2. Blunt injury to the chest with closed epiglottis
Iatrogenic
Injury Causing IGE/AGE
1. Pulmonary over pressurization by positive ventilation
of a patient or diving barotrauma.
2. Slippage of air into a vein or artery by surgical procedure
or catheterization.
3. Insufflation by gas of body cavity or organ cavity:
Pneumoencephalogram
Endometrial/fallopian insufflation
Bowel, bladder, vaginal, or peritoneal cavity insufflation
Gaseous emission from laser vapor
All tissues, including bone, are susceptible to IGE/AGE.
In fact, IGE/AGE may involve the spinal cord or the brain.
IGE/AGE can produce a spectrum of injury ranging from a transient
ischemic attack-like event (TIA), to a major stroke. (A small
stroke can also occur.) When the involvement includes the
nervous system or heart, a potential life threatening condition
exists. The spectrum of IGE/AGE symptomatology extends from
simple malaise to full neurologic and cardiovascular collapse.
Gas emboli found in IGE/AGE may impede
blood and lymphatic flow by partially or completely obstructing
the vessel lumen. The gas emboli result in damage to the
vascular endothelial lining which elicits an immune response
and a decreased or obstructed blood supply which triggers
an ischemic response. Like decompression illness, separated
gas within the blood can stimulate a procoagulative state
and trigger an inflammatory response. Even if gas emboli
resolve, either spontaneously or as a result of hyperbaric
oxygen treatment, reperfusion injury in the affected area
will likely occur.
Two types of tissue become important during
recovery from CNS IGE/AGE. The umbra, is a region of ischemically
destroyed or infarcted tissue and is surrounded by the penumbra,
a region of viable yet functionally impaired tissue. Acutely,
the penumbra may be underperfused and susceptible to conversion
to umbra due to a lack of oxygen or energy. Penumbral regions
of a CNS injury have been found to fill with polymorphonuclear
leukocytes and macrophages. In the early post IGE/AGE period,
extravasated leukocytes in an ischemic neurologic tissue
function as an oxygen sink. The goal of hyperbaric oxygen
therapy is to minimize conversion of penumbral to umbral
tissue in regions of marginal brain or spinal cord oxygenation.
Hyperbaric oxygen therapy may also prevent leukocyte adherence
and truncate lipid peroxidation in the injured region and
attenuate the progression of ischemic injury and possible
penumbral conversion to umbra.
IGE/AGE exists in three phases,
acute (0 to 15 days), subacute (16 days to six months), and
chronic (greater than six months). The acute recovery period
may include an early phase covering the first six hours after
embolic occlusion, during which the penumbral regions are
at greatest risk of conversion to umbral regions. If these
regions survive longer than six hours, they usually revert
to "ex-penumbra" regions. Hyperbaric oxygen therapy
may immunomodulate the "ex-penumbra" and speed
the recovery to normal neurologic tissue. Further understanding
of the mechanisms of IGE/AGE neurologic injury and recovery
may lead to current treatment modifications or new treatment
modalities. Thus far, the use of pharmacologic agents have
been disappointing in IGE/AGE patients. Drugs have failed
to ameliorate acute, subacute and chronic neurologic IGE/AGE
injury, and recompression is the only successful therapy.
Some investigators have shown encouraging clinical results,
in patients with residual neurologic damage treated with
a series of "tailing" low-dose hyperbaric oxygen
treatments (1.5 to 2.5).
Venous gas embolism poses a greater
threat to life than AGE only when larger quantities of gas
are involved. Venous gas microembolism is often equated with
decompression illness. Subclinical venous gas microembolism
may be a part of every decompression. For repetitive air
dives, decompression from most allowable bottom times may
produce pulmonary arterial bubbles detectable with Doppler
evaluation.
A patent foramen ovale is present in approximately
34 percent of the adult population. A patent foramen ovale
would allow a venous bubble to cross into the arterial circulation.
Over pressurization of the pulmonary artery may temporarily
pneumatically block the pulmonary vasculature and allow build
up of intravascular gas emboli in the precapillary bed. A
sudden release of the high pressures would allow intravascular
emboli to cross the pulmonary vascular filter.
References
Archer J, Rhodes V: The grief process and job loss: A cross-sectional
study. Br J Psychol 84:395-410, 1993.
Armon C, Deschamps C,
Adkinson C: Hyperbaric treatment of cerebral air embolism
sustained during an open heart surgical procedure. Mayo
Clinic Proceedings 66:565-571, 1991.
Baggish MS, Daniell JF:
Death caused by air embolization associated with neodymium-aluminum-garnet
laser surgery and artificial sapphire tips. Am J Obstet Gynecol
161:877-878, 1989.
Baker BB, Awwad EE: Computed tomography
of fatal cerebral air embolism following percutaneous aspiration
biopsy of the lung. J Computer Assisted Tomography 12(6):1082-1083,
1988.
Barghage TE, Vorosmarti J, Barnard EEP: An evaluation
of recompression treatment tables. Naval Med Res Inst Bethesda,
MD, 1978:1-82.
Barnett HJM, Elasziw M, Meldrum HE: Drugs and
surgery in the prevention of ischemic stroke. New Engl J
Med 332(4):238-248, 1995.
Baskin SE, Wozniak RF: Hyperbaric
oxygenation in the treatment of hemodialysis-associated air
embolism. New Engl J Med 293(4):184-185, 1975.
Bennett PB,
Miler J, Fegraeus L: Saturation therapy in decompression
sickness, in: Lambertson CJ (ed): Decompression sickness
and its therapy. Allentown: Air Products and Chemicals, 1979,
pp 79-95.
Bernhardt TL, Goldman RW, Thumbs PA: Hyperbaric
oxygen treatment of cerebral air embolism from urogenital
sex during pregnancy. Crit Care Med 16:729-730, 1988.
Blanco
CE, Rietveld LA, Ruys JH: Systemic air embolism: A possible
complication of artificial ventilation. Acta Paediatr Scand
68:925-927, 1979.
Bove AA, Clark JM, Simon AJ: Successful
therapy of cerebral air embolism with hyperbaric oxygen at
2.8 ATA. Undersea Biomed Res 9:75-80, 1982.
Boysen G, Overgaard
K: Thrombolysis in ischemic stroke.how far from a clinical
breakthrough? J Intern Med 237:95-103, 1995.
Bray P, Myers
RAM, Coulee RA: Orogenital sex as a cause of non-fatal air
embolism in pregnancy. Obstet Gynecology 61(5):653-657, 1983.
Brott
T, Adema HP, Olinger CP: Measurements of acute cerebral infarction:
A clinical examination scale. Stroke 20:864-870, 1989.
Calverley
RK, Dodds WA, Trapp WG: Hyperbaric treatment of cerebral
air embolism: A report of a case following cardiac catheterization.
Canada Anesth Soc J 18(6):665-674, 1971.
Campbell PR, Kerridge
R: Fatal traumatic air embolism following a stab wound to
the chest. Aust NZ J Surg 63:307-309, 1993.
Carlton PW, Hallenbeck
JM, Flynn: Pathogenesis and treatment of cerebral air embolism
and associated disorders. Bethesda: US Naval Medical Research
Institute Report 84-20, 1984.
Cummins RO (ed): Advanced Cardiac
Life Support Textbook. Dallas: American Heart Association,
1994, pp 1-17.
Curley MD, Schwartz HJ, Zwiingleberg KM: Neuropsychologic
assessment of cerebral decompression sickness and gas embolism.
Undersea Biomed Res 15:223-236, 1988.
Davis PE, Piantadosi
CA, Moon RE. Treatment of severe neurological DCI with saturation
vs. multiple short tables. Journal UHMS 21(Sup):93, 1994.
Dunford
RG, Waccholz C, Huggins K, Bennett PB: Doppler analysis of
sport diver profiles: A second look. Undersea Biomed Res
19(Sup):70, 1992.
Durant TM, Long J, Oppenheimer MJ: Pulmonary
(venous) air embolism. Am Heart J 33(4):269-281, 1947.
Durant
TM, Oppenheimer MJ, Webster MR: Arterial air embolism. Am
Heart J 38:481-500, 1949.
Dutka AJ: Air or gas embolism, in:
Camporesi, EM, Barker AC (eds): Hyperbaric oxygen therapy,
a critical review. Bethesda: UHMS, 1991 pp 1-10.
Eastman AB: Advanced Trauma
Life Support®, Student Manual. Chicago: American
College of Surgeons Committee on Trauma, 1993, pp 19-37.
Ericsson
JA, Gottlieb JD, Sweet RB: Closed chest cardiac massage in
treatment of venous air embolism. New Engl J Med 270:1353-1354,
1964.
Evans DE, Kobrine AI, LeGrys DC: Protective effect of
lidocaine in acute cerebral ischemia induced by air embolism.
J Neurosurg 60:257-263, 1984.
Evans RD, Palazzo MG, Ackers JW: Air embolism during total
hip replacement, comparison of two surgical techniques. Br
J Anaesth 62:243-247, 1989.
Fuerdi GA, Czarnecki DJ, Kindle EP: MR findings in the brains
of compressed air workers: Relationship to psychometric results.
Am J Neuroradiol 12:67-70, 1991.
Flynn ET: Decompression sickness, in: Camporesi EM, Barker
AC (eds): Hyperbaric oxygen therapy, a critical review. Bethesda:
UHMS 1991, pp 55-74.
Ginsburg MD, Yao H, Markgraf CG: Pathophysiological significance
of circulatory alterations in the focal ischemic penumbra,
in: Tomitam, Mahedlishvili G, Rosenblum W, Heiss WD (eds):
Microcirculatory stasis in the brain. Amsterdam: Excerpta
Medica, 1993, pp 249-259.
Goulian M, Narailhat F, Rapin M: Embolies gazeuses probables
on cours d.insufflation pour coelioscopie. Presse Med 77:1035,
1969.
Gouze FJ: Air embolism in a diver. US Navy Med Bull 43(3):538-542,
1944.
Grinden AJ: Adverse reactions to whole blood donation and
plasmapheresis. Crit Rev Clin Lab Sci, 17(1):51-75, 1982.
Gronert GA, Messick JM, Cucchiara RF, Michenfelder JD: Paradoxical
air embolism from a patent foramen ovale. Anesthesiology
50:548-549, 1979.
Hagen PT, Scholz DG, Edwards WD: Incidence and size of patent
foramen ovale during the first ten decades of life: An autopsy
study of 965 normal hearts. Mayo Clin Proc 59:17-20, 1984.
Hall ED, Braughler JM, McCall JM: Role of oxygen radicals
in stroke: effects of the 21-aminosteroids (lazaroids). A
novel class of antioxidants. Prog Clin Biol Res 351-362,
1990.
Hallenbeck JM, Dutka AJ, Tanishima T: Polymorphonuclear leukocyte
accumulation in brain regions with low blood flow during
the early postischemic period. Stroke 17:246-253, 1986.
Halperin P, Greenstein A, Melamed Y: Arterial air embolism
after penetrating lung injury. Crit Care Med 11(5):392-393,
1983.
Harch PG, Van Meter KW, Gottlieb SF, Staab P: The effect
of tailing treatment on neurological residual and SPECT brain
images in type II (cerebral) DCI/CAGE. Undersea Hyperbaric
Med 21(Sup):22-23, 1994.
Hart GB: Treatment of decompression illness and air embolism
with hyperbaric oxygen. Aerospace Med 45:1190-1193, 1974.
Helps SFC, Gorman DF: Air embolism of the brain in rabbits
pretreated with mechlorethamine. Stroke 33:351-354, 1991.
Hills BA, Butler BD: Size distribution of intravascular air
emboli produced by decompression. Undersea Biomed Res 8(3):163-170,
1981.
Hossman KA: Viability thresholds and the penumbra of focal
ischemia. Ann Neurol 36:557-565, 1994.
Ingvar DH, Adolfson J, Lindermark C: Cerebral air embolism
during training of submarine personnel in free escape: An
electroencephalographic study. Aerosp Med 44:628-635, 1973.
LaCelle PL: Alterations by leukocytes of erythrocyte flow
in microchannels. Blood Cells 12:179-189, 1986.
Lassen NA, Fieschi C, Lanzi GL. Ischemia, penumbra, and neuronal
death: Comments on the therapeutic window in acute stroke
with particular reference to thrombolytic therapy. Cerebrovasc
Dis 1(1):3-35, 1991.
Lee HC, Miu KC, Chen SH: Therapeutic effect of type II decompression
sickness, a comparative study between United States Navy
treatment table 6A and modified treatment table 6A1. J Hyperbaric
Med 3(4):235-242, 1988.
McCulloch J: Excitatory amino acid antagonists and their
potential for the treatment of ischemic brain damage in man.
Br J Clin Pharmacol 34:106-114, 1992.
Marini JJ, Culver BH: Systemic gas embolism complicating
mechanical ventilation in the adult respiratory distress
syndrome. Ann Intern Med 110:699-703, 1989.
Michenfelder JD, Martin JT, Altenburg BM: Air embolism during
neurosurgery. J Am Med Assn 208(8):1353-1358, 1969.
Miller JN, Fagraeus L, Bennett PB: Nitrogen-oxygen saturation
therapy in serious cases of compressed air decompression
sickness. Lancet 2:169-171, 1978.
Moon RE, Camporesi EM, Erwin CW: Use of evoked potentials
during acute dysbaric sickness in: Halsey MJ, Elliot DH (eds):
Diagnostic techniques in diving neurology. London: Medical
Research Council 1987 pp 63-69.
Muir KW, Lees KR: Clinical experience with excitatory amino
acid antagonist drugs. Stroke 26:503-513, 1995.
Myers R, Monjil LG, Cullen BM: Macrophage and astrocyte populations
in relation to [3H]PK 11 195 binding in rat cerebral cortex
following a local ischemic lesion. J of Cereb Blood Flow
Metab 11:314-322, 1991.
Myers RAM: Hyperbaric chambers, United States and Canada.
Bethesda: Undersea Hyperbaric Medical Society, 1993.
Nori R, Alati GL, Dolde G: Pulmonary gas embolism during
pneumoencephalography. Minerva Anesthesia 45(5):323-328,
1979.
Parewijck W, Thiery M, Tumperman J: Serious complications
of laparoscopy. Med Sci Law 19:199-201, 1979.
Philip RB: A review of blood changes associated with compression-decompression:
relationship to decompression sickness. Undersea Biomed Res
1:117-150, 1974.
Polak B, Adams H: Traumatic air embolism in submarine escape
training. US Navy Bull 30(1):164-177, 1932.
Ruesch M. Miyatake BS, Ballinger CM: Continuing hazard of
air embolism during pressure transfusions. J Am Med Assn
172(14):476-482, 1960.
Schlaepfer K: Air embolism following various diagnosis of
therapeutic procedures in diseases of the pleura and the
lung. John Hopkins Hospital Bulletin 33:321-330, 1982.
Seritt S: Fatal road accidents: Injuries, complications and
causes of death in 250 subjects. Br J Surg 55:480-509, 1968.
Thom SR, Elbuken ME: Oxygen dependent antagonism of lipid
peroxidation. Free Radic Biol Med 10:413-426, 1991.
Thom SR, Mendiguren I, Nebolon M: Temporary inhibition of
human neutrophil B2 integrin function by hyperbaric oxygen
(HBO). Clin Res 42:130A, 1994.
Thomas AN, Stephens BG: Air embolism: A case of morbidity
and death after penetrating chest trauma. J Trauma 14(4):633-638,
1974.
Thomas AN, Stephens BG: Air embolism: A cause of morbidity
and death after penetrating chest trauma. J of Trauma 14(8):663-668,
1974.
Thorsen T, Brubakk A, Ovstedal T, Farstad M, Holmsen H: A
method for production of N2 microbubbles in platelet-rich
plasma in an aggregometer-like apparatus and effect on the
platelet density in vitro. Undersea Biomed Res 13:271-288,
1986.
Thorsen T, Dalen H, Bjerkvig R, Holmsen H: Transmission and
scanning electron microscopy of N2 microbubble-activated
human platelets in vitro. Undersea Biomed Res 14(1):45-66,
1987.
Tomatis L, Nemiroff M, Riahi M: Massive arterial air embolism
due to rupture of pulsatile assist device: Successful treatment
in the hyperbaric chamber. Ann Thoracic Surg 32:604-608,
1981.
USN Diving Manual, Vol I (Air Diving) Revision 3, 1993, NAVSEA
0994-LP-001-9110, Section 8C (Recompression Therapy) pp 8-29
to 8-72.
Van Meter K. Edgar End Memorial Lecture: A better end: high
dose/low dose sequential hyperbaric oxygen therapy respectively
in acute and convalescing CNS injury. 1991 ACHM Annual Scientific
Meeting, Ft. Lauderdale, FL, 1991.
Van Meter K, Harch P, Weiss L: 14 year experience of the
use of a tailing of hyperbaric oxygen treatments to lessen
or resolve neurologic residual injury in arterial gas embolism
(AGE) or decompression illness (DCI) in the acute 0-15 day
and sub-acute 16 day to 6 month post-injury period. Proceedings
of the 1995 Gulf Coast Chapter of the UHMS. New Orleans:
UHMS, 1995. (in press).
Van Meter K. Medical field management of the injured diver,
in: Moon RE, Camporesi EM (eds): Problems in respiratory
care: clinical applications of hyperbaric oxygen. Philadelphia:
J.B. Lippincott Co. 1991, 4(2):253-268.
Van Meter K, Harch P, Gottlieb S: Use of hyperbaric oxygen
to improve patient placement on the oxygen dose response
curve during advanced cardiac life support during resuscitation
from cardiopulmonary arrest, in: Jain, KK (ed): Hyperbaric
Oxygen Therapy (in press).
Van Meter KW: Two diving accident case histories, in: Miller
JN, Parmentier JL (eds): Rehabilitation of the paralyzed
diver. (UHMS Workshop #30, Point Clear, Ala.) Bethesda: UHMS,
1984 pp 25-30.
Van Meter, K: Diving accident management, first aid and medical
evacuation in diving accident management in Moon RE, Bennett
PB (eds): Proc UHMS Workshop. Bethesda: UHMS, 1990 pp 162-188.
Vourc.h G, Berreti E, Trichet B: Two unusual cases of gas
embolism following urethral surgery under laser. Intensive
Care Med 8:239-240, 1982.
Ward CA, Fraser WD, McCullough D: Effect of mild pressure
profiles on complement activation and sensitivity. Undersea
Hyperbaric Med 20:54-55, 1993.
Ward MK, Shadforth M, Hill AVL: Air embolism during haemodialysis.
Br Med J 3:74-78, 1971.
Warren LP, Djang WT, Moon RE: Neuro imaging of diving injuries
to the central nervous system. Am J Neuroradiol 9:933-938,
1988.
Warren RB, Philip RB, Inwood MJ: The ultrastructural morphology
of air embolism platelet adhesion to the interface and endothelial
damage. Br J Exp Path 54:163-172, 1973.
Yeakel AE. Lethal air embolism from plastic blood-storage
container. J Am Med Assn 204(3):175-177, 1968.
Zamboni WA, Roth AC, Russel RC: Morphologic analysis of the
microcirculation during reperfusion of ischemic skeletal
muscle and the effect of hyperbaric oxygen. Plast Reconstr
Surg 91:1110-1123, 1993.
Carbon Monoxide Poisoning
Carbon monoxide
(CO) remains among the most common poisons in the industrialized
world and a leading cause of poison-related deaths. A survey of death certificate
reports in the United States for a 10 year period ending in 1988 indicated
that CO exposure contributed to the deaths of more than 56,000 people. Automotive
exhaust, home heating, and industrial exposure are the most common sources.
Fumes from paint strippers containing methylene chloride are metabolized to
carbon monoxide (CO) in the body and can cause severe poisoning. Flu-like symptoms
may occurs without fever. Headache, nausea, vomiting, weakness, and collapse
often are followed by coma and death. The diagnosis cannot be made unless exposure
is suspected. The skin is cherry red after death; however, this is not seen
clinically. The percentage of carboxyhemoglobin (COHb)in the blood does not
correlate with the prognosis and often does not correspond to the clinical
condition caused by tissue toxicity resulting from disruption of cellular cytochrome
metabolism and initiation of lipid peroxidation. HBOT is indicated in the presence
of almost any sign or symptom (even if the patient looks well). The sooner
HBOT is initiated, the better. The mortality rate in severe cases is 13.5%
when HBO is initiated < 6 hours and 30.1% when initiated > 6 hours after
rescue.
Neurological and psychiatric abnormalities
also occur in delayed fashion after patients are acutely
treated for CO poisoning and, seemingly, have recovered.
These delayed neurological sequelae (DNS) occur from two
to 40 days after CO exposure. Manifestations of DNS include
disorientation, apathy, bradykinesia, gait disturbances,
aphasia, apraxia, incontinence, personality changes, and
rarely, seizures and coma. The incidence of DNS was 35.8
percent for those patients treated with either ambient pressure
oxygen or with HBOT at greater than six hours. In contrast,
the incidence of DNS among patients treated with HBOT in
less than six hours was 7 percent.
The physiological benefits
of hyperbaric oxygen therapy (HBOT) are: improvement of oxygenation
and hastened COHb dissociation, restoration of mitochondrial
function, and inhibition of adherence of leukocytes to the
microvascular endothelium.
References
Bour H, Pasquier P, Bertrand-Handy J: Le coma oxycarbone. Semaine des Hopitaux
de Paris. 40:1839-1861, 1966.
Broome JR, Skrine H, Person RR: Carbon monoxide poisoning: forgotten not gone.
Br J Hosp Med 39:298-305, 1988.
Brown, DB, Mueller GL, Golich FC: Hyperbaric oxygen treatment for carbon monoxide
poisoning in pregnancy: a case report. Aviat Space Environ Med 63:1011-1014,
1992.
Brown SD, Piantadosi CA: In vivo binding of carbon monoxide to cytochrome C oxidase
in rat brain. J Appl Physiol 68:604-610, 1990.
Cho SH, Yun DR: The experimental study on the effect of the hyperbaric oxygenation
on the pregnancy wastage of the rats in acute carbon monoxide poisoning. Seoul
J Med 23:66-75, 1982.
Choi IS: Delayed neurologic sequelae in carbon monoxide intoxication. Arch Neurol
40:433-435, 1983.
Cobb N, Etzel RA: Unintentional carbon monoxide-related deaths in the United
States, 1979 through 1988. JAMA 266:659-663, 1991.
Coburn RF: The carbon monoxide body stores. Ann NY Acad Sci 174:11-22, 1970.
Cramlet SH, Erickson HH, Gorman HA: Ventricular function following acute carbon
monoxide exposure. J Appl Physiol 39:482-486, 1975.
Elkharrat D, Raphael JC, Korach JM, et al.: Acute carbon monoxide intoxication
and hyperbaric oxygen in pregnancy. Inten Care Med 17:289-292, 1991.
Ferm VH: Teratogenic effects of hyperbaric oxygen. Proc Soc Exp Biol Med 116:975-976,
1964.
Forbes WH, Sargent F, Roughton FJW: The rate of carbon monoxide uptake in normal
men. Am J Physiol 143:594, 1945.
Gilman SC, Bradley ME, Greene KM, Fischer GJ: Fetal development: effects of decompression
sickness and treatment. Aviat Space Environ Med 54:1040-1042, 1983.
Gorman DF, Clayton D, Gilligan JE, Webb RK: A longitudinal study of 100 consecutive
admissions for carbon monoxide poisoning to the Royal Adelaide Hospital. Anaesth
Intens Care 20:311-316, 1992.
Goulon M, Barois A, Rapin M, Nouailhat F, Grosbuis S, Labrousse J: Carbon monoxide
poisoning and acute anoxia due to breathing coal gas and hydrocarbons. Ann Med
Int (Paris) 120:335-349, 1969, translated in J Hyperbaric Med 1:23-41, 1986.
Hardy KR, Thom SR: Pathophysiology and treatment of carbon monoxide poisoning.
Clin Toxicol 32: 613-629, 1994.
Ischiropoulos H, Duran D, Nelson J, Beers MF, Abrams WR, Ohnishi ST, Fisher D,
and Thom SR: Nitrotyrosine as a marker of in vivo peroxynitrite formation and
oxidative stress. J Biol Chem (in press).
Ishimaru H, Katoh A, Suzuki H, Fukuta T, Kameyama T, Nabeshima T: Effects of
N-methyl-D-aspartate receptor antagonists on carbon monoxide-induced brain damage
in mice. J. Pharmacol Exp Ther 261:349-352, 1992.
Koren G, Sharav T, Pastuszak A, Garrettson LK, Hill K, Samson I, et al.: A multicenter,
prospective study of fetal outcome following accidental carbon monoxide poisoning
in pregnancy. Reprod Toxicol 5:397-403, 1991.
Krantz T, Thisted B, Strom J, Sorensen MB: Acute carbon monoxide poisoning. Acta
Anaesthesiol Scand 32:278-282, 1988. Lamy M, Hauguet M: Fifty patients with carbon
monoxide intoxication treated with hyperbaric oxygen therapy. Acta Anes Belgica
1:49-53, 1969.
Mathieu D, Nolf M, Durocher A: Acute carbon monoxide poisoning: risk of late
sequelae and treatment by hyperbaric oxygen. Clin Toxicol 23:315-324, 1985.
Mayevsky A, Meilin S, Rogatsky GG, Zarchin N, Thom SR: Multiparametric monitoring
of the awake brain exposed to carbon monoxide. J Appl Physiol (in press).
Min SK: A brain syndrome associated with delayed neuropsychiatric sequelae following
acute carbon monoxide intoxication. Acta Psychiatr Scand 173:80-86, 1986.
Murray LP, Hofrichter J, Henry ER, Eaton WA: Time-resolved optical spectroscopy
and structural dynamics following photodissociation of carbonmonoxyhemoglobin.
Biophys Chem 29:63-76, 1988.
Myers RAM, Snyder SK, Emhoff TA: Subacute sequelae of carbon monoxide poisoning.
Ann Emerg Med 14:1163-1167, 1985.
Norkool DM, Kirkpatrick JN: Treatment of acute carbon monoxide poisoning with
hyperbaric oxygen: a review of 115 cases. Ann Emerg Med 14:1168-1171, 1985.
Norman CA, Halton DM: Is carbon monoxide a workplace teratogen? A review and
evaluation of the literature. Ann Occup Hyg 34:335-347, 1990.
Raphael, JC, Elkharrat D, Jars-Guincestre MC, Chastang C, et al.: Trial of normobaric
and hyperbaric oxygen for acute carbon monoxide intoxication. Lancet 19:414-419,
1989.
Richardson JC, Chambers RA, Heywood PM: Encephalopathies of anoxia and hypoglycemia.
Arch Neurol 1:178-182, 1959.
Silverman CS, Brenner J, Murtagh FR: Hemorrhagic necrosis and vascular injury
in carbon monoxide poisoning: MR demonstration. AJNR 14:168-170, 1993.
Smith JS, Brandon S: Morbidity from acute carbon monoxide poisoning at three-year
follow-up. Br Med J 1:318-321, 1973.
Thom SR: Functional inhibition of leukocyte B2 integrins by hyperbaric oxygen
in carbon monoxide-mediated brain injury in rats. Toxicol Appl Pharmacol 123:248-256,
1993.
Thom SR: Leukocytes in carbon monoxide-mediated brain oxidative injury. Toxicol
Appl Pharmacol 123:234-247, 1993.
Thom SR, Mendiguren I, Nebolon M, Campbell D, Kilpatrick L: Temporary inhibition
of human neutrophil B2 integrin function by hyperbaric oxygen (HBO). Clin Res
42:130A, 1994.
Thom SR, Ischiropoulos H: Nitric oxide released by platelets inhibits neutrophil
B2 integrin function following acute carbon monoxide poisoning. Toxicol Appl
Pharmacol 128:105-110, 1994.
Thom SR, Taber RL, Mendiguren II, Clark JM, Hardy KR, Fisher AB: Delayed neuropsychological
sequelae following carbon monoxide poisoning and its prophylaxis by treatment
with hyperbaric oxygen. Ann Emer Med 25:474-480, 1995.
Tomaszewski C, Rudy J, Wathen J, Brent J, Rosenberg N: Prevention of neurologic
sequelae from carbon monoxide by hyperbaric oxygen in rats. Ann Emer. Med 21:631-632,
1992.
VanHoesen KB, Camporesi EM, Moon RE, Hage ML, Piantadosi, CA: Should hyperbaric
oxygen be used to treat the pregnant patient for acute carbon monoxide poisoning.
JAMA 261:1039-1043, 1989.
Zhang J, Piantadosi CA: Mitochondrial oxidative stress after carbon monoxide
hypoxia in the rat brain. J Clin Invest 90:1193-1199, 1991.
Clostridial
Myonecrosis (Gas Gangrene) Clostridium
perfringens is the most common cause of gas gangrene, -although one or more
other anaerobic organisms are usually present. The syndrome is primarily
mediated by a toxin, lecithinase, which lyses Red Blood Cells (RBCs) and
severely damages muscle, cell membranes, and the kidney. Profound shock that
responds only to whole blood or packed RBCs can occur. Death may ensue within
6 hours of diagnosis unless immediate treatment is given. The prognosis is
especially grave in an elderly compromised host who has gangrene of the abdomen
or trunk. The usefulness of HBOT in gas gangrene has been demonstrated in
good animal studies and large clinical series. If used, HBOT must be carried
out early in the course of the disease before surgical debridement. Surgery
requiring general anesthesia should generally be deferred until after the
first 2 or 3 HBOT treatments are given, because surgery entails a delay in
HBOT, and further spread of the infection and systemic toxicity may ensue.
Furthermore, the demarcation between viable and necrotic tissue is clearer
after 2 HBOT treatments, often making possible less disfiguring surgery and
salvage of entire limbs. . Risk of death in a patient with truncal gangrene
is 75% if HBOT is -initiated > 24 hours after diagnosis
and < 18% if initiated within 24 hours. When a limb is involved, the mortality
rate may be > 9% if HBOT is delayed > 24 hours, but it approaches zero
if initiated in <24 hours, regardless of the type or time of surgery.
The action of hyperbaric oxygen on Clostridia (and other anaerobes) is based
on the formation of oxygen free radicals in the absence of free radical degrading
enzymes, such as superoxide dismutases, catalases, and peroxidases.
References
Bakker DJ: The use of hyperbaric oxygen in the treatment of certain infectious
diseases, especially gas gangrene and acute dermal gangrene. Wageningen, Holland:
Drukkerij Veenman BV, 1984.
Bakker, DJ: Clostridial myonecrosis, in: Davis JC, Hunt TK (eds): Problem wounds:
The role of oxygen. New York: Elsevier, 1988, pp 13-172.
Bakker DJ: Clostridial myonecrosis, in Davis JC, Hunt TK, (eds): Problem Wounds:
the Role of Oxygen. New York: Elsevier, 1988 pp 153-172.
Balldin U, Hedstrum SA, Lundgren C, Thomson D: Cases of gas gangrene treated
with hyperbaric oxygen. Nord Med 79:589, 1968.
Bayliss GJ, Cass C: Hyperbaric oxygen used in the treatment of gas gangrene.
Med J Aust 2:991, 1967.
Bernhard WF, Filler RM: Hyperbaric oxygenation: current concepts. Am J Surg 115:661,
1968.
Brummelkamp, WH, Hogendijk J, Boerema I: Treatment of anaerobic infections (clostridial
myositis) by drenching the tissues with oxygen under high atmospheric pressure.
Surgery 49:299-302, 1961.
Brummelkamp WH: Considerations on hyperbaric oxygen therapy at three atmospheres
absolute for clostridial infections type welchii. Ann NY Acad Sci 117:688-699,
1965.
Darke SG, King AM, Slack WK: Gas gangrene and related infection: classification,
clinical features and aetiology, management and mortality. A report of 88 cases.
Br J Surg 64:104, 1977.
Demello FJ, Hashimoto T, Hitchcock CR, Haglin JJ: The effects of hyperbaric oxygen
on germination and toxin production of Clostridium perfringen spores, in: Wada
J, Iwa JT (eds): Proceedings of the Fourth International Congress on Hyperbaric
Medicine. Baltimore, MD: Williams & Wilkins Co., 1970, pp 276.
Demello FJ, Haglin JJ, Hitchcock CR: Comparative study of experimental Clostridium
perfringens infection in dogs treated with antibiotics, surgery and hyperbaric
oxygen. Surgery 73:936-941, 1973.
Demello FJ, Hashimoto T, Hitchcock CR, Haglin JJ: The effect of hyperbaric oxygen
on the germination and toxin production of Clostridium perfringens spores, in:
Wada J, Iwas T, (eds): Proceedings of the Fourth International Congress on Hyperbaric
Medicine. Tokyo. Igaku Shoin Ltd., 1970 pp 276.
Duff JH, Shibata HR, Vanschaik L, Usher R, Wigmore RA, MacLean LD: Hyperbaric
oxygen: a review of treatment in eighty-three patients. Can Med Assn J 97:510,
1967.
Encinas CM, Herrero MJ, Sanchez GU, Ortiz MF, Santidrian MJP, Quesada SA: Gas
producing necrotizing infections. Role of hyperbaric oxygen. Med Clin 90:316,
1988.
Gibson A, Davis FM: Hyperbaric oxygen therapy in the management of Clostridium
perfringens infections. NZ Med J 99:617, 1986.
Guidi ML, Proiette R, Carducci P, Magalini SI, Pelosi G: The combined use of
hyperbaric oxygen, antibiotics and surgery in the treatment of gas gangrene.
Resuscitation 9:267, 1981.
Hart GB, Lam RC, Strauu MB: Gas gangrene. J Trauma 23:991, 1983.
Hart GB, Lamb RC, Strauu MB: Gas gangrene I A collective review. II A 15-year
experience with hyperbaric oxygen. J Trauma 23:991-1000, 1983.
Hart GB, O.Reilly RR, Cave RH, Broussard ND: The treatment of clostridial myonecrosis
with hyperbaric oxygen. J Trauma 14:712, 1974.
Heimbach RD: Gas gangrene: Review and update. HBO Rev 1(1) 41-46 30, 1980.
Hill GB, Osterhout S: Experimental effects of hyperbaric oxygen on selected clostridial
species, I in vitro studies and II in vivo studies in mice. J Infec Dis 125:17-35,
1972.
Hill GB, Osterhout S: In vitro and in vivo experimental effects of hyperbaric
oxygen Clostridium perfringens, in: Brown IW, Cox BG (eds): Proceedings of the
Third International Congress on Hyperbaric Medicine, Publ No. 1404. Washington,
DC: National Academy of Sciences, National Research Council, 1966, pp 538-543.
Hirn M, Niinkoski J: Hyperbaric oxygen in the treatment of clostridial gas gangrene.
Ann Chir Gynecol 77:37, 1988.
Hitchcock CR, Demello EJ, Haglin JJ: Gangrene infection. New approaches to an
old disease. Surg Clin N Am 55(6):1043-1410, 1975.
Holland JA, Hill GB, Wofle WG, Osterhout S, Saltzman HA, Browns IV: Experimental
and clinical experience with hyperbaric oxygen in the treatment of clostridial
myonecrosis. Surgery 77:75-85, 1975.
Jeffrey JS, Thomson S: Gas gangrene in Italy. A study of 33 cases treated with
penicillin. Br J Surg 32:159, 1944.
Kaye D: Effect of hyperbaric oxygen on Clostridia in vitro and in vivo. Pro Soc
Exp Biol 124:360-366, 1967.
Kelley HG, Pace WG: Treatment of anaerobic infections in mice with hyperpressure
oxygen. Surg Forum 14:46-47, 1963.
Kindwall EP: Gas gangrene: Acute medical emergency: the role of hyperbaric oxygen.
Wis Med J 69:261, 1970.
Kivisaari J, Niinikoski J: Use of silastic tube and capillary sampling technique
in the measurement of tissue PO2 and PCO2. Am J Surg 125:623-627, 1973.
Klopper PJ: Hyperbaric oxygen treatment after ligation of the hepatic artery
in rabbits, in: Boerema I, Brummelkamp WH, Meijne NG (eds): Clinical application
of hyperbaric oxygen. Amsterdam: Elsevier, 1964 pp 31-35.
Lamy M, LeJeune G, Noel FX, Carlier P: Gas gangrene: importance of early diagnosis
hyperbaric oxygen therapy. Rev Med Liege 32:589, 1977.
McLeod JW: Variations in the periods of exposure to air and oxygen necessary
to kill anaerobic bacteria. Acta Pathol Microbiol Scan 3(Supp):255, 1930.
MacLennan JD: the histotoxic clostridial infections of man. Bacteriol Rev 26:177-276,
1962.
Maudsley RH: Proceedings: post-operative gas gangrene managed by hyperbaric oxygen.
J Bone Jt Surg Br 57:251, 1975.
Nier H, Kremer K: Der Gasbrand-weiterhin ein diagnostisches und therapeutisches
problem. Zentrabl Chir 109;402-417, 1984.
Nier H, Sailer R, Palomba P: Hyperbaric oxygen treatment in gas gangrene. Dtsch
Med Wochenschr 103:1958, 1978
Nora PF, Mousavipour M, Laufman H: Mechanisms of action of high pressure oxygen
in Clostridium perfringens exotoxin toxicity, in: Brown IW, Cox BG (eds): Hyperbaric
Medicine, Publ. No. 1404. Washington DC: National Academy of Sciences, National
Research Council 1966, pp 544-51.
Nora PF, Mousavipour M, Mittlepunkt A, Rosenburg M, Laufman H: Brain as target
organ in Clostridium perfringens cytotoxin. Arch Surg 92:243-246, 1966.
Pailler JL, Labeau F: La gangrene gazeuse: Une affection militaire? Acta Chir
Belg 86:63-71, 1986.
Peirce EC II: Gas gangrene. A critique of therapy. Surg Rounds 1984; 7:17-25.
Roding B, Groenveld PHA, Boerema I: Ten years of experience in the treatment
of gas gangrene with hyperbaric oxygen. Surg Gynecol Obstet 134:579, 1972.
Sailer R, Junemann A, Ghazwinian R: Therapy of gas gangrene. Comparison of results
of standard and hyperbaric oxygen therapy. Med Kin 69:1620, 1974.
Schoemaker G: Oxygen tension measurements under hyperbaric conditions, in: Boerema,
Brummelkamp WH, Meijne NG (eds). Clinical application of hyperbaric oxygen. Amsterdam:
Elsevier, 1964, pp 330-335.
Schott H: Die gasbrand infection hefte unfalheik. Prinzipien der Behandlung,
Ergbrisse 138:179-186, 1979.
Sheffield PJ: Tissue oxygen measurement, in: Davis JC, Hunt TK (eds): Problem
Wounds: Role of Oxygen. New York: Elsevier, 1988, pp 17-51.
Slack WK, Hanson GC, Chew HE: Hyperbaric oxygen in the treatment of gas gangrene
clostridial infection. A report of 40 patients treated in a single-person hyperbaric
oxygen chamber. Br J Surg 56:505, 1969.
Tooley AH, Watt J: Hyperbaric oxygen therapy: review of the present position
and experience in the management of naval patients. JR Nav Med Serv 54:101, 1968.
Unsworth IP, Sharp PA: Gas Gangrene. An 11-year review of 73 cases managed with
hyperbaric oxygen. Med J Aust 140: 256, 1984.
Van Unnik AJM: Inhibition of toxin production in Clostridium perfingens in vitro
by hyperbaric oxygen. Antonie Leewenhoek Microbiol 31:181-186, 1965.
Van Zijl JJW: Discussion of hyperbaric oxygen, in: Brown IW, Cox BG (eds): Proceedings
of the Third International Conference on Hyperbaric Medicine. Washington, D.C.:
National Academy of Sciences, National Research Council, 1966, pp 552-54.
Weinstein L, Barza, MA: Medical intelligence. Current concepts: Gas gangrene.
NEJM 289:1129-1131, 1973.
Willis AT: Clostridia of wound infection. London: Butterworth, 1969:490.
Compromised Skin
Grafts and Flaps: Reconstructive
Work
Skin grafts and compromised skin flaps represent a classical
problem involving insufficient oxygen supply to tissue.
Plastic surgeons use the grafts and flaps to repair serious
damage, and to close or cover wounds. In creating skin
grafts or flaps, a strip of skin is sharply removed from
all or part of its adjacent tissues. The surgery removes
all of the blood supply from the skin graft, and eradicates
much of the blood supply in the skin flap.
Skin grafts are
especially susceptible to hypoxic injury. Once a graft is
in place, the bed and the edges of the graft site provide
the only sustenance available until neovascularization occurs.
Hyperbaric oxygen therapy (HBOT) maximizes oxygen transfer
for these sites. HBOT ameliorates vascular problems triggered
by hypoxia. Three of the primary effects of HBOT, hyperoxygenation,
edema reduction, and neovascularization, prove particularly
useful to surgeons and plastic surgeons.
Providing hyperoxgenation
increases the oxygen tension in the graft bed and wound margins
up to 1500 percent. In turn, the hyperoxygenation causes
a marked increase in the effectiveness of the blood or plasma
that reaches the graft through compromised blood vessels.
The volume of tissue that derives sufficient oxygen from
a single damaged blood vessel increases 16 fold, and marked
tissue salvage results. This same effect maximizes the rate
new blood vessels mature at the site where the graft ultimately
attaches.
Hyperbaric techniques also offer strategies
for reducing edema. The edema reduction effect, induced by
the relative spasm of a precapillary arteriolar sphincter,
helps to limit the swelling of the graft or flap. In addition,
an increase in the mean diffusion radii occurs, resulting
in the amount of tissue being supplied with oxygen increasing
significantly. The high oxygen tensions achievable with HBOT
induce large oxygen gradients, increasing macrophage migration,
proline synthesis, and neovascularization. Once this neovascularization
occurs, the beneficial effects of HBOT for organs begins.
Among other things, fluids begin to flow to tissues and organs
more readily, limiting damage from reperfusion injury.
Skin
grafts, by their very nature, hypoxic. Grafts are used to
cover areas that are devoid of skin due to trauma or disease,
so the recipient site is ischemic, and it is this site that
will provide the support for the graft. The skin graft is
cut from all of its blood supply. Next, it is placed upon
the compromised tissue base, where it must initially rely
completely upon oxygen that diffuses from the base, and later
upon rapid angiogenesis from the base and wound margins so
that the graft's vascular structure can be reconstructed.
Skin flaps must overcome similar problems due to the stretching
and twisting of their vascular tree.
HBOT ameliorates the
hypoxia, post-operative swelling, and ischemia of grafts
and flaps. HBOT provides high concentrations of oxygen to
the graft bed so that more oxygen can diffuse into the graft
to sustain it during an ischemic period. The anti-edema effect
of HBOT improves tissue oxygenation by reducing the distance
oxygen must diffuse, and by improving perfusion.
The benefit
of HBOT for the preparation of a base for skin grafting and
the preservation of compromised skin grafts has been well
documented as effective.
References
Bowersox JCC, Strauss MB, Hart GB: Clinical experience with hyperbaric oxygen
therapy in the salvage of ischemic skin flaps and grafts. J Hyperbaric Medicine
1:141-149, 1986.
Collins TM, Caimi R, Lynch PR, et al.: The effects of nicotinamide and hyperbaric
oxygen on skin flap survival. Scand J Plast Reconstr Hand Surg 5-7, 1991.
Davis JC, Hunt, TK: Hyperbaric Oxygen Therapy. Bethesda: Undersea and Hyperbaric
Medical Society, 1977, pp 229-238.
Fisher B, Jian KK, Braun E, Lehri S: Handbook of Hyperbaric Oxygen Therapy. Berlin:
Springer-Verlag, 1988, pp 109-111.
Gottrup F, Firmin R, Hunt TK: The dynamic properties of tissue oxygen in healing
flaps. Surgery 527-536, 1984.
Gruber RP, Brinkley FB, Amato JJ, et al.: Hyperbaric oxygen and pedicle flaps,
skin grafts, and burns. Plast Reconstr Surg 24-30, 1970.
Hill RK, Bright DE, Neubauer RA: Use of hyperbaric oxygen in the reanastomosis
of the severed ear: a review. J Hyperbaric Medicine 4(4):163-175, 1990.
Hunt TK, van Winkle W Jr.: Wound healing normal repair, in Dunphy JE (ed): Fundamentals
of Wound Management in Surgery. South Plainfield: Chirurgecom, 1976, 1-68.
Hunt TK., Pai MP: The effect of varying ambient oxygen tensions on wound metabolism
and collagen synthesis. Surg Gynecol Obstet 561-567, 1972.
Jain KK: Textbook of Hyperbaric Medicine. Toronto: Hogrefe and Huber, 1990, pp
345-348.
Jurell G, Kaijser L: The influence of varying pressure and duration of treatment
with hyperbaric oxygen on the survival of skin flaps: an experimental study.
Scan J Plast Reconstr Surg 7:25-28, 1973.
Kaelin CM, Im MJ, Myers RAM, et al.: The effects of hyperbaric oxygen on free
flaps in rats. Arch Surg 607-609, 1990.
Knighton DR, Silver IA, Hunt TK: Regulation of wound healing angiogenesis: Effect
of oxygen gradients and inspired oxygen concentrations. Surgery 262-70, 1981.
Mader JT : Hyperbaric Oxygen Therapy A Committee Report. Bethesda: Undersea and
Hyperbaric Medical Society, 1989, pp 69-75.
McFarlane RM, Wemuth RE: The use of hyperbaric oxygen to prevent necrosis in
experimental pedicle flaps and composite skin grafts. Plast Reconstr Surg 37:422-430,
1966.
Nemiroff PM, Merwin, GE, Brant T, Cassisi NJ: HBO and irradiation on experimental
skin flaps in rats. Surg Forum 35:549-550, 1984.
Nylander G, Lewis D, Nordstrom H, Larsson J: Reduction of postischemic edema
with hyperbaric oxygen. Plast Reconst Surg 596-601, 1985.
Perrins DJD, Cantab MB: Influence of hyperbaric oxygen on the survival of split
thickness skin grafts. Lancet 1:868-871, 1967.
Perrin DJD: Influence of hyperbaric oxygen on the survival of split thickness
skin grafts. Lancet 868-871, 1967.
Perrins DJD: The effect of hyperbaric oxygen on ischemic skin flaps, in: Grabb
WC, Myers MB (eds): Skin Flaps. Boston: Little Brown & Co., 1975, 53-63.
Reedy MK, Capen CV, Bakker DP, et al.: Hyperbaric oxygen therapy following radical
vulvectomy: an adjunctive therapy to improve wound healing. Gynecologic Surg
13-16, 1994.
Reinisch JF: Pathophysiology of skin flap circulation. Plast Reconstr Surg 54:585,
1974.
Rubin JS, Marzella L, Myer RAM, Suter C, et al.: Effects of hyperbaric oxygen
on the take of composite skin grafts in rabbit ears. J Hyperbaric Medicine 3:79-88,
1988.
Sheffield PJ: Tissue oxygen measurements with respect to soft-tissue wound healing
with normobaric and hyperbaric oxygen. Hyperb Oxygen Review 18-46, 1985.
Zamboni WA, Roth AC, Russell RC, Nemiroff PM, et al.: The effect of acute hyperbaric
oxygen therapy on axial pattern skin flap survival when administered during and
after total ischemia. J Reconstr Micros 5:343-347, 1989.
Zamboni WA: Hyperbaric oxygen reduces ischemia-induced skeletal muscle injury.
Plast Recontr Surg 609-609, 1996.
Zamboni WA, Roth AC, Russell RC, et al.: Morphologic analysis of the microcirculation
during reperfusion of ischemic skeletal muscle and the effect of hyperbaric oxygen.
Plast and Reconstr Surg 1110-1123, 1993.
Decompression
Illness
Decompression illness (DCI) is an affliction of gas separation
causing bubbles (foreign bodies) in the tissues and blood resulting from a
decrease in ambient pressure. The gas separation results in a number of responses
ranging from an immune "foreign body" response, ischemia, and finally
a reperfusion injury. The separation of gas, to form bubbles in the blood or
tissue, impedes blood and lymphatic flow by direct mechanical obstruction,
as well as directly disrupts or distorts tissues when intratissue bubble formation
occurs. Intravascular gas perturbs the vessel.s endothelial surface and the
cell surfaces of the platelets and white blood cells. Should recompression
relieve the bubble(s), a reperfusion injury in the affected area will likely
occur.
Often, intravascular gas embolism (IGE) complicates DCI
and may result from either a variant of DCI or a complication arising from
separate, concurrent pulmonary barotrauma with gas embolization. Intravascular
gas embolic occlusion potentially blocks off-gassing tissue areas during decompression
and may potentiate the local DCI injury in the involved area.
All tissues, including
bone, are susceptible to DCI. When the involvement includes the nervous system
or heart, a potential life threatening condition exists. The spectrum of DCI
symptomatology extends from simple malaise to full cardiovascular collapse.
Central nervous system (CNS) injury may be subtle or blatant and peripheral
nerves may be involved. DCI may also present as a variant of the systemic inflammatory
response syndrome.
DCI has classically been categorized into Type I and Type
II (and recently Type III when the injury occurs concurrent with and is complicated
by intravascular gas embolism. Type I involves joints and their ligaments,
lymphatics, and skin. Type II involves the central nervous system (brain and
spinal cord, autonomic nervous system, and peripheral nervous system), the
lungs (chokes), and the cardiovascular system.
Recompression treatment in acute
DCI has three main effects bubble compression, aerobic support for ischemic
tissues, and an anti-inflammatory effect. Recompression causes reduction of
the size of bubbles in tissues and in vessels in accordance with the ideal
gas law. Besides shrinking the bubbles mechanically to improve liquid flow,
their resulting smaller size forces them back into solution. Recompression
provides aerobic support by filling the plasma fraction of blood with an increased
content of dissolved oxygen to support the oxygen needs of downstream tissues.
This also promotes the diffusion of the inert gas out of the separated gas
phase bubble, and facilitates the blockade of potential inflammatory mediators.
Hyperbaric oxygen therapy blunts leukocyte adhesion and blocks lipid peroxidation.
Thus, hyperbaric oxygen therapy recompression allows dissolution of the separated
gas and attenuates the inflammatory response which occurs during reperfusion
of acutely injured ischemic tissue.
DCI may involve the spinal cord or the brain.
DCI can produce a spectrum of injury ranging from a transient ischemic attack-like
event (TIA), a small stroke, or a major stroke. CNS ischemia produces two zones
of injury. The umbra, is a region of ischemically destroyed or infarcted tissue
and is surrounded by the penumbra, a region of viable, yet functionally impaired
tissue. Penumbral regions of a CNS injury have been found to fill with polymorphonuclear
leukocytes (PMN's) and macrophages. In the early post DCI period, extravasated
leukocytes in an ischemic CNS tissue function as an oxygen sink. The goal of
hyperbaric oxygen therapy is to minimize conversion of penumbral to umbral
tissue in regions of marginal oxygenation in the brain or spinal cord.
The DCI
injury involves acute, subacute, and chronic phases. Further understanding
of the immune/ inflammatory processes may lead to modifications of current
treatments or new treatment modalities. Thus far, the use of pharmacologic
agents has been disappointing in DCI patients. Drugs have failed to ameliorate
acute, subacute, and chronic neurologic DCI injury. Recompression is the only
effective treatment of this devastating disease.
Lymphocytes can be immunomodulated
by different oxygen tensions. Subacutely and chronically they may roam the
penumbra much as they would in a healing wound. If perfusion of the penumbra
is not re-established, then dysfunctional regions of poorly perfused neuronal
tissue may never again become functional. Successful reperfusion modulated
by lymphocytes, macrophages and fibroblasts may account for the accelerated
recovery in neurologically injured DCI patients undergoing a "tailing" series
of hyperbaric oxygen treatments. New capillary growth in the ground substance
matrix can be accelerated in ischemically injured CNS tissue undergoing hyperbaric
oxygen therapy. However, the gradual recovery in a few patients with untreated
severe neurological injuries from DCI was observed at the turn of the century.
References
Archer J, Rhodes V. The grief process and job loss A cross-sectional study. Br
J Psychol 1993;84395-410.
Barghage TE, Vorosmarti J, Barnard EEP An evaluation of recompression treatment
tables. Naval Med Res Inst Bethesda, MD, 19781-82.
Barnett HJM, Elasziw M, Meldrum HE Drugs and surgery in the prevention of ischemic
stroke. N Engl J Med 332(4)238-248, 1995.
Blick G Notes on divers paralysis. Brit Med J 21796-1798, 1909.
Bove AA The basis for drug therapy in decompression sickness. Undersea Biomed
Res 9(2)91-111, 1982.
Boysen G, Overgaard K Thrombolysis in ischemic stroke.how far from a clinical
breakthrough? J Intern Med 23795-103, 1995.
Brom JR, Dutka AJ, McNamee GA Exercise conditioning reduces the risk of neurologic
decompression illness in swine. Undersea Hyperbaric Med 22(1)73-85, 1995.
Carlton PW, Hallenbeck JM, Flynn ET, Bradley ME, Evans DE Pathogenesis and treatment
of cerebral air embolism and associated disorders. Betheda US Naval Medical Research
Institute Report 84-20, 1984.
Cohen SN The neurologic examination Practical points part 1 & 2. Hospital
Med 23(9)(10)21-42, 1987.
Cross MR, Pimlott JK Pressure induced changes in blood cell rigidity; a mechanism
for causing aseptic bone necrosis in Bove AA, Bacharach AJ, Greenbaum LJ (eds)
Underwater and hyperbaric physiology ix. Bethesda UHMS, 1987, 345-358.
Cummins RO (ed) Advanced Cardiac Life Support Textbook. Dallas American Heart
Association, 1994, pp 1-17.
Curley MD, Schwartz HJ, Zwiingleberg KM Neuropsychologic assessment of cerebral
decompression sickness and gas embolism. Undersea Biomed Res 15223-236, 1988.
Davis PE, Piantadosi CA, Moon RE Treatment of severe neurological DCI with saturation
vs. multiple short tables. UHMS J, 21(Sup)93, 1994.
Eastman AB Advanced Trauma Life Support®, Student Manual. Chicago American
College of Surgeons Committee on Trauma, 1993, pp 19-37.
Fuerdi GA, Czarnecki DJ, Kindwall EP MR findings in the brains of compressed
air workers Relationship to psychometric results. Am J Neuroradiol 1267-70, 1991.
Gersh I, Hawkineon GE, Rathburn EN Tissue and vascular bubbles after decompression
from high pressure atmospheres.correlation of specific gravity with morphological
changes. J Cellular Compar Physiol 2455-61, 1994.
Golding FC, Griffiths PD, Hempleman HV, Patron WD, Walder DN Decompression sickness
during the construction of the Dartford Tunnel. Br J Ind Med 17167-180. 1960.
Gorman DF A proposed classification of the decompression illness, in Francis
TJR, Smith DJ (eds) Describing Decompression Illness (UHMS Workshop, Alverstoke
UK). Bethesda UHMS 1990, pp 6-9.
Hall ED, Braughler JM, McCall JM Role of oxygen radicals in stroke Effects of
the 21-aminosteroids (lazaroids). A novel class of antioxidants. Prog Clin Biol
Res 351-362, 1990.|
Hallenbeck JM, Dutka AJ, Tanishima T Polymorphonuclear leukocyte accumulation
in brain regions with low blood flow during the early postischemic period. Stroke
17246-253, 1986.
Heimbecker RO, Lemire G, Chen CH Role of gas embolism in decompression sickness.a
new look at "the bends." Surgery 64(1)264-272, 1968.
Hossman KA Viability thresholds and the penumbra of focal ischemia. Ann Neurol
36557-565, 1994.
Kerut E, Truax W, Borreson T, Van Meter K Patent foramen ovale (PFO) and decompression
sickness. Undersea Hyperbaric Med 22(Sup)36, 1995.
Kihara M, McManus PG, Schmelzer JD Experimental ischemic neuropathy salvage with
hyperbaric oxygen. Ann Neurol 37(1)89-94, 1995.
Lee AK, Hester RB, Coggin JH Increased oxygen tensions modulate the cellular
composition of the adaptive immune system in BALB/c mice. Cancer Biotherapy 8(3)241-252,
1993.
Lee AK, Hester RG, Coggin JH, Gottlieb SF Increased oxygen tensions influence
subset composition of the cellular immune system in aged mice. Cancer Biotherapy
9(1)39-54, 1994.
Lee HC, Miu KC, Chen SH Therapeutic effect of type II decompression sickness,
a comparative study between United States Navy treatment table 6A and modified
treatment table 6A1. J Hyperbaric Med 3(4)235-242, 1988.
Levin LL, Stewart GJ, Lynch PR, Bove AA Blood and blood vessel wall changes induced
by decompression sickness in dogs. J Appl Physiol 50944-949, 1981.
McCulloch J Excitatory amino acid antagonists and their potential for the treatment
of ischemic brain damage in man. Br J Clin Pharmacol 34106-114, 1992.
Mackay CR Honing of naïve, memory and effector lymphocytes. Curr Opin Immunol
5423-427, 1993.
Madsen J, Hink J, Hyldegaard O Diving physiology and pathophysiology. Clin Physiol
14547-626, 1994.
Mebane GY, McIver NKI Fitness to dive, in Bennett P, Elliot D (eds) The Physiology
and Medicine of Diving. London WB Saunders, 1993, pp 53-76.
Miller JN, Fagraeus L, Bennett PB Nitrogen-oxygen saturation therapy in serious
cases of compressed air decompression sickness. Lancet 2169-171, 1978.
Moon RE, Camporesi EM, Erwin CW Use of evoked potentials during acute dysbaric
sickness, in Halsey MJ, Elliot DH (eds) Diagnostic techniques in diving neurology.
London Medical Research Council, 1987, pp 63-69.
Muir KW, Lees KR Clinical experience with excitatory amino acid antagonist drugs.
Stroke 26503-513, 1995.
Myers R, Monjil LG, Cullen BM Macrophage and astrocyte populations in relation
to [3H]PK 11 195 binding in rat cerebral cortex following a local ischemic lesion.
J Cereb Blood Flow Metab 11314-322, 1991.
Myers RAM Hyperbaric chambers, United States and Canada. Bethesda Undersea and
Hyperbaric Medical Society, 1993.
Neuman TS, Bove AA Combined arterial gas embolism and decompression sickness
following no-stop dives. Undersea Biomed Res 17(S)429-436, 1990.
Philip RB A review of blood changes associated with compression-decompression
relationship to decompression sickness. Undersea Biomed Res 1117-150, 1974.
Shields TG, Lee WB The incidence of decompression sickness arising from commercial
offshore air-diving operations in the UK sector of the North Sea diving 1982-83,
Robert Gordon.s Institute of Technology and National Healthboard Report .
Smith LA, Hardman JM, Sandberg GD, Beckman EL Is acute bone decompression sickness
initiated by bubbles and hemorrhages? Undersea Biomed Res 19(Sup)69, 1992.
Sub Sea Medical Manual, Fourth Edition. Ecosystem treatment table 7A. Sub Sea
Publications, 1992, pp 7-19 to 7-20.
Teasdale G, Jennett B Assessment of coma and impaired consciousness A partial
scale. Lancet 281-84, 1974.
Thom SR, Elbuken ME Oxygen dependent antagonism of lipid peroxidation. Free Radical
Biol Med 10413-426, 1991.
Thom SR, Mendiguren I, Nebolon M Temporary inhibition of human neutrophil B2
integrin function by hyperbaric oxygen (HBO). Clin Res 42130A, 1994.
Thom SR Hyperbaric Oxygen Therapy, A Committee Report. Bethesda UHMS, 1992, pp
71-80.
Thomsen T, Ovsteda IT, Vereide A, Holmsen H Effects of platelet antagonists on
the reduction in platelet density caused by microbubbles in vitro. Undersea Biomed
Res 13(3)289-303, 1986.
Thorsen T, Dalen H, Bjerkvig R, Holmsen H Transmission and scanning electron
microscopy of N2 microbubble-activated human platelets in vitro. Undersea Biomed
Res 14(1)45-66, 1987.
USN Diving Manual, Vol I (Air Diving) Revision 3, NAVSEA 0994-LP-001-9110, Section
8C (Recompression Therapy) 1993. pp 8-29 to 8-72.
Van Meter K Medical field management of the injured diver, in Moon RE, Camporesi
EM (eds) Problems in respiratory care clinical applications of hyperbaric oxygen.
Philadelphia J.B. Lippincott Co., 1991, 4(2)253-268.
Van Meter K Edgar End Memorial Lecture A better end high dose/low dose sequential
hyperbaric oxygen therapy respectively in acute and convalescing CNS injury.
ACHM Annual Scientific Meeting, Ft. Lauderdale, FL, 1991.
Van Meter K Medical field management of the injured diver. Problems Respiratory
Care 4(2)253-268, 1991.
Van Meter K, Harch P, Gottlieb S Use of hyperbaric oxygen to improve patient
placement on the oxygen dose response curve during advanced cardiac life support
during resuscitation from cardiopulmonary arrest, in Jain KK, (ed) Hyperbaric
Oxygen Therapy (in press).
Van Meter K, Harch P, Weiss L 14 year experience of the use of a tailing of hyperbaric
oxygen treatments to lessen or resolve neurologic residual injury in arterial
gas embolism (AGE) or decompression illness (DCI) in the acute 0-15 day and sub-acute
16 day to 6 month post-injury period, in Proceedings of the 1995 Gulf Coast Chapter
of the UHMS. New Orleans 1995, (in press).
Van Meter KW Two diving accident case histories, in Miller JN, Parmentier JL
(eds) Rehabilitation of the paralyzed diver (UHMS Workshop #30, Point Clear,
Alabama). Bethesda UHMS, 1984, pp 25-30..
Vann RD Hypobaric decompression sickness workshop, in Pilmanas AA (ed) Proceedings
of Workshop held at Armstrong Laboratories, Brooks AFB, TX, 16-18th October,
1990. Bethesda UHMS, pp 165.
Warren LP, Djang WT, Moon RE Neuro imaging of diving injuries to the central
nervous system. Am J Neuroradiol 9933-938, 1988.
Zamboni WA, Roth AC, Russel RC Morphologic analysis of the microcirculation during
reperfusion of ischemic skeletal muscle and the effect of hyperbaric oxygen.
Plast Reconstr Surg 911110-1123, 1993.
Osteoradionecrosis
The recent introduction
of radiation therapy for the treatment of solid tumors allows
previously untreatable cancers to be cured. Now physicians
face the challenge of aiding survivors. Unfortunately, the
radiation beam used to fight cancer damages more than the
tumor. Normal tissue in the path of the beam often sustains
damage. Destruction of tissue also occurs. Even today, many
physicians consider chronic radiation effects as irreversible,
but hyperbaric oxygen therapy (HBOT) offers opportunities
to repair damage.
Both bone and soft tissue suffer damage
from therapeutic radiation. Bone is 1.8 times as dense as
soft tissue and thereby absorbs a proportionately larger
dose of incident radiation than does soft tissue.
High doses
of radiation cause a proliferative endarteritis causing ischemia,
and eventually death of bone in the distribution of the involved
blood supply. Additionally, radiation upsets the normal balance
of osteoclastic destruction and osteoblastic reconstruction
occurring in bone. Cell death of these osteocytes and osteoblasts
leads to osteoporosis and eventually to osteonecrosis.
Clinically
significant osteonecrosis (ORN) usually develops over a period
ranging from four months to several years. There is no satisfactory
treatment for radiation necrosis using available conventional
means. One barrier to healing involves nutrients providing
adequate nutrition and oxygen to radiation devascularized
tissue presented a previously insurmountable challenge. Radiation
ulcers are painful, and the prolonged use of narcotic analgesics
can lead to addiction. High failure rates confront reconstructive
surgeons working in irradiated areas, due to problems with
healing.
Osteoradionecrosis becomes clinically
significant when it develops at four anatomic sites chest
wall, mandible, pelvis, vertebral column, and skull. Damage
to the ribs and sternum can result following radiation therapy
for tumors of the breast, chest wall, or lung. Pathologic
fractures in irradiated ribs can result from coughing, or
from merely deep breathing.
Irradiation damage to the skull
from treatment of orbital or brain tumors is rare, primarily
because of the use of highly fractionated doses of radiation,
but does occur. The radiotherapy treatment of pelvic neoplasms
can lead to radionecrosis of the lumbar vertebrae, femur,
or pelvis; pathologic stress fractures can result from injury
to these weight-bearing structures. Doses of radiation necessary
to produce adequate tumor kill in head and neck cancers are
accompanied by an unfortunately high incidence of osteoradionecrosis.
The mandible is often involved following radiotherapy of
these tumors, and is over represented in osteoradionecrosis.
Osteoradionecrosis
most commonly involves the mandible. The mandible is often
involved because head and neck cancers are common, and radiation
therapy in these cancers is very effective. Most cases of
mandibular osteoradionecrosis originate from tooth extraction
after development of radiation caries. The trauma of tooth
extraction causes a breakdown of gum tissue and subsequent
progressive bone necrosis. Exposed bone is often visible.
Granulation tissue cannot form a bridge over dead bone, and
the infection continues despite meticulous wound care and
antibiotics; the resolution rate is only about 8% without
HBOT.
Because the clinical and the radiographic
pictures fail to match and no laboratory tests or reliable
irradiation tissue tolerance curves exist, physicians rely
on a simple working definition of osteoradionecrosis. Any
exposed bone in a field of irradiation failing to heal after
a trial of conservative treatment earns the ORN label. So
does the presence of radiographically demonstrated osteoradionecrosis.
Beginning
in 1979, Marx and others demonstrated that osteoradionecrosis
is a wound healing defect related to a chronic hypoxic state.
In 1984, Marx published a study of 150 cases of osteoradionecrosis
in the mandible. In his examination, Marx divided the disease
into three stages of advancing clinical activity. This staging
and the HBOT treatment of osteoradionecrosis he described
became the standard for planning the treatment of mandibular
and soft tissue ORN. The strategy has implications for the
treatment of ORN in other tissues as well.
The 1990 Consensus
Paper of the National Cancer Institute on the Oral Complications
of Cancer therapies states "The treatment of ORN with antibiotics and surgical
debridement frequently fails, with progressive involvement of the remaining mandible.
The keystone of the treatment of ORN is the provision of adequate tissue oxygenation
in the damaged bone. This is best done by using hyperbaric oxygen therapy (HBOT).
In the event that dental extractions are required following radiation, meticulous
surgical technique and antibiotic prophylaxis are necessary."
References
Beehler MR, Max RE Hyperbaric oxygen induced angiogenesis and fibroplasia in
human irradiated tissues, in Proceedings of the 65th Meeting of the American
Association of Oral and Maxillofacial Surgery, 1983, pp 78-79.
Davis, JC, Hunt TK (eds) Problem Wounds The Role of Oxygen. New York Elsevier,
1988, pp 65-110.
Friedman RB Osteoradionecrosis Causes and Prevention. NCI Monograph 1990 9145-149.
Hart GB, Mainous EG Treatment of radiation necrosis with hyperbaric oxygen. Cancer
372580, 1976.
Hart GB, Strauss MB Hyperbaric oxygen in the management of radiation injury,
in Schmutz J (ed) Proceedings of the First Swiss Symposium on Hyperbaric Medicine.
Stiftung für Hyperbare Medizin. Basel 1986, pp. 31-51.
Kaufman T, Hirshowitz B, Monies-Chass I Hyperbaric oxygen for post-irradiation
osteomyelitis of the chest wall. Harefuah 97220-222, 1979.
Mainous EG, Hart GB Osteoradionecrosis of the mandible Treatment with hyperbaric
oxygen. Arch Otolaryngol 101173, 1975.
Mainous EG, Boyle PJ Hyperbaric oxygen in total rehabilitation of patients with
mandibular osteoradionecrosis. Int J Oral Surg 3297, 1974.
Marx RE A new concept in the treatment of osteoradionecrosis. J Oral Maxillofac
Surg 41351, 1983.
Marx RE, Johnson RP, Kline SN Prevention of osteoradionecrosis A randomized prospective
clinical trial of hyperbaric oxygen versus penicillin. J Am Dental Assn 11149,
1985.
Marx RE Osteoradionecrosis A new concept of its pathophysiology. J Oral Maxillofac
Surg 48283, 1983.
Marx RE Osteoradionecrosis of the jaws Review and update. Hyperbaric Oxygen Rev
578-126, 1984.
Myers, RAM, Marx RE Use of hyperbaric oxygen in postradiation head and neck surgery.
NCI Monograph 19909,151-157.
National Cancer Institute Consensus Development Conference on Oral Complications
of Cancer Therapies Diagnosis, Prevention, and Treatment. National Cancer Institute
Monographs 19909,3-8.
Phemister DB Radium necrosis of the bone. Am J Roentgenol 16340, 1926. Stampfli
WP, Kerr HD Fracture of the femoral neck following pelvic irradiation. AM J Roentgenol
5771-83, 1947.
Progressive
Necrotizing Infection (Meleney's ulcer)
The term "Meleney's ulcer" describes
a distinct pathological entity also called progressive bacterial synergistic
gangrene.
The diagnostic criteria for Meleney's ulcer, as described
in the literature, would include (1) a slowly progressive, superficial necrotizing
process; (2) evidence of a variety of micro-areophilic, anaerobic, facultative,
or amoebic organisms; (3) hypoxic wound environment, and (4) microvascular
thrombosis in a full thickness ulcer.
Some diabetic foot ulcerations may meet
the criteria for designation as a Meleney's ulcer. All diabetic ulcerations
are not automatically Meleney's ulcers. Although all diabetic ulcer wounds
are hypoxic and have microvascular thrombosis, a particular wound must also
have an expanding margin, because progressive necrosis is the sine qua non
of Meleney's ulcer.
The mechanisms by which HBOT exerts a beneficial effect
for Meleney's ulcer treatment are similar to those already described for other
necrotizing infections. In the acute phase, HBOT (1) inhibits growth of anaerobic
or micro-aerophilic antibiotic organisms, (2) enhances neutrophil function
compromised by hypoxia, and (3) increases the efficacy of certain antibiotics
(particularly those requiring oxygen dependent intracellular transport). Once
spread of the necrotic process has been halted, HBOT may promote healing by
stimulating angiogenesis and granulation tissue formation, as in other conditions.
Meleney
Ulcer is an old term used as a description of a rare progressive cutaneous
infection. Doctors Frank Meleney and George Brewer described this clinical
entity in 1926 as a synergistic necrotizing bacterial infection. They defined
it as a progressively expanding infection created by the synergism between
aerophilic and anaerobic/microaerophilic bacteria. The eponymic term, Meleney
Ulcer, is no longer commonly used, and has been supplanted by Progressive Necrotizing
Infection.
The utility of hyperbaric oxygen therapy (HBOT) in progressive
necrotizing infections is very well established in the medical literature.
HBOT is adjunctive to the standard surgical and antibiotic therapy.
References
Daly, JW, King CR, Monif GRG Progressive necrotizing wound infections in postirradiated
patients. Obstet Gynecol 52(1)5S-8S), 1978.
Davison J, Jones DM, Turner L Diagnosis of Meleney's synergistic gangrene. Br
J Surg 75267-271, 1988.
Eltorai IM, Hart GB, Strauss MB, Montroy R, Juler GL The role of hyperbaric oxygen
in the management of Fournier.s gangrene. Int Surg 7153, 1986.
Grainger RW, MacKenzie DA, McLachlin AD Progressive bacterial synergistic gangrene
Chronic undermining ulcer of Meleney. Canad J Surg 10439-444, 1967.
Iorianni P, Oliver GC Synergistic soft tissue infections of the perineum. Dis
Colon Rectum 640-644, 1992.
Kingston D, Seal DV Current hypotheses on synergistic microbial gangrene. Br
J Surg 77260-264, 1990.
Maisel RH, Karlen R Cervical necrotizing fasciitis. Laryngoscope 795-798, 1994.
Reigels-Nielsen P, Hesselfeldt-Nielson J, Bang-Jensen E, Jacobsen E Fournier's
gangrene 5 patients treated with hyperbaric oxygen. J Urol 132918, 1984.
Riseman JA, Zamboni WA, Curtis A, et al. Hyperbaric oxygen therapy for necrotizing
fasciitis reduces mortality and the need for debridements. Surgery 108847-850,
1990.
Sandusky WR Frank L. Meleney Pioneer Surgeon-Bacteriologist. Arch Surg 118151-155,
1983.
Shupak A, Greenberg E, Hardoff R et al. Hyperbaric oxygenation for necrotizing
(malignant) otitis externa. Arch Otolaryngol Head Neck Surg 1470-1475, 1989.
Spirnak JP, Resnick MI, Hampel N, Persky L Fournier's gangene report of 20 patients.
J Urol 131289, 1984.
Zamboni WA, Riseman JA, Kucan JO Management of Fournier.s gangrene and the role
of hyperbaric oxygen. J Hyper Med 177-185, 1990.
Burns
The use of hyperbaric oxygen therapy
in the treatment of thermal burns began in 1965 when Ikeda
and Wada observed more rapid healing of second-degree burns
in a group of coal miners who were being treated for carbon monoxide poisoning.
Subsequent studies demonstrated that hyperbaric oxygen therapy, when used as
an adjunct in a comprehensive program of burn care, can significantly improve
morbidity and mortality, reduce length of hospital stay, and lessen the need
for surgery. Deep second-degree burns may deteriorate to full-thickness loss,
and HBOT may be considered to reduce hypoxia and edema formation by preserving
ATP and aerobic glycolysis. HBOT also reduces the fluid requirement by 35%
within the first 24 hours. To be most effective, HBOT must be started within
24 hours of the burn, preferably as soon as possible. Additionally, hypertrophic
scarring and contracture are reduced. Fluid resuscitation must be continued
without interruption while the patient is in the chamber. The patient must
also be protected from heat loss. HBOT for serious burns should only be used
in a critical care setting.
References
Alexander JW, Meakins JL A physiological basis for the development of opportunistic
infections in man. Annals of Surgery 176273, 1972.
Alexander JW, Wilson D Neutrophil dysfunction and sepsis in burn injury. Surg
Gynec Obstet 130431, 1970.
Arturson G Pathophysiology of the burn wound. Ann Chir Gynaecol 69178, 1980.
Arturson G The pathophysiology of severe thermal injury. J Burn Care Rehab 6(2)
129, 1985.
Bleser F, Benichoux R Experimental surgery the treatment of severe burns with
hyperbaric oxygen. J Chir (Paris) 106281, 1973.
Boykin JV, Eriksson E, Pittman RN In vivo microcirculation of a scald burn and
the progression of post burn dermal ischemia. Plast. Reconstr. Surg 66191, 1980
Brown IW, Cox BG (eds) Proceedings of the Third International Congress on Hyperbaric
Medicine, Publ No. 1404. Washington, DC National Academy of Sciences, National
Research Council, 1966, pp 611.
Cianci P, Lueders H, Lee H, et al. Adjunctive hyperbaric oxygen reduces the need
for surgery in 40-80 percent burns. J. Hyperbar Med 397, 1988.
Cianci P, Lueders H, Lee H Hyperbaric oxygen and burn fluid requirements observations
in 16 patients with 40-80 percent TBSA burns. Undersea Biomed Research Suppl.
1514, 1988.
Cianci P, Lueders HW, Lee H, et al. Adjunctive hyperbaric oxygen therapy reduces
length of hospitalization in thermal burns. J Burn Care Rehabil 10432, 1989.
Cianci P, Williams C, Lueders H. et al. Adjunctive hyperbaric oxygen in the treatment
of thermal burns an economic analysis. J Burn Care Rehabil 11140, 1990.
Cianci P, Sato R, Green B Adjunctive hyperbaric oxygen reduces length of hospital
stay, surgery, and the cost of care in severe burns. Undersea Biomed Research
Suppl 18108, 1991.
Deitch E, Wheelahan T, Rose M,. et al. Hypertrophic burn scars analysis of variables.
J Trauma 23S895, 1983.
Grim P S, Nahum A, Gottlieb L, et al. Lack of measurable oxidative stress during
HBOT therapy in burn patients. Undersea Biomed Res Suppl (16)22, 1989.
Grogan JB Altered neutrophil phagocytic function in burn patients. J Trauma 16734,
1976.
Grossman AR Hyperbaric oxygen in the treatment of burns. Annals of Plastic Surgery
1163, 1978.
Grossman AR, Grossman A J Update on hyperbaric oxygen and treatment of burns.
Hyperbaric Oxygen Review 351, 1982.
Gruber RAP, Brinkley B, Amato JJ, et al. Hyperbaric oxygen and pedicle flaps,
skin grafts, and burns. Plast. Reconstr. Surg 4524, 1970.
Hammarlund C, Svedman C, Svedman P Hyperbaric oxygen treatment of healthy volunteers
with UV-irradiated blister wounds. Burns 17296, 1991.
Hart GB, O.Reilly RR, Broussard ND, et al. Treatment of burns with hyperbaric
oxygen. Surg Gynecol Obstet 139693, 1974.
Hartwig VJ and Kirste G Experimentele untersuchungen uber die revaskularisierung
von verbrennungswunden unter hyperbarer sauerstofftherapie. Zbl Chir 991112,
1974
Heggers JP, Robson, MC, Zachary LS Thromboxane inhibitor for the prevention of
progressive dermal ischemia due to the thermal injury. J Burn Care Rehabil 6466,
1980.
Hohn DC, MacKay RD, Halliday B, et al. Effect of oxygen tension on the microbicidal
function of leukocytes in wounds and in vitro. Surg Forum 2718, 1976.
Ikeda K, Ajiki H, Nagao H, et al. Experimental and clinical use of hyperbaric
oxygen in burns, in Wada J, Iwa T (eds) Proceedings of the Fourth International
Congress on Hyperbaric Medicine. Tokyo Igaku Shoin Ltd., 1970, p 370.
Ikeda K, Ajiki H, Kamiyama T, et al. Clinical application of oxygen hyperbaric
treatment. Geka (Japan) 29 1279, 1967.
Iwa T Discussion in Brown JW, Cox BG (eds) Proceedings of the Third International
Congress on Hyperbaric Medicine. Washington, DC, 1966.
Kaiser VW, Schnaidt U, von der Leith H Auswirkungen hyperbaren sauerstoffes auf
die fresche brandwunde. Handchir Mikrochir Plast Chir 21158, 1989.
Ketchum SA, Zubrin JR, Thomas AN, et al. Effect of hyperbaric oxygen on small
first, second and third degree burns. Surg Forum 1865, 1967.
Ketchum SA, Thomas AN, Hall AD Angiographic studies of the effect of hyperbaric
oxygen on burn wound revascularization, in Wada J and Iwa T (eds) Proceedings
of the Fourth International Congress on Hyperbaric Medicine. Tokyo Igaku Shoin
Ltd., 1980, p 388.
Korn HN, Wheeler ES, Miller TA Effect of hyperbaric oxygen on second degree burn
wound healing. Arch Surg 112732, 1977.
Lamy ML, Hanquet MM Application opportunity for OHP in a general hospital - a
two years experience with a monoplace hyperbaric oxygen chamber, in Wada J and
Iwa T (eds) Proceedings of the Fourth International Congress on Hyperbaric Medicine
(1970). Tokyo Igaku Shoin, Ltd., p 517.
Mader JT, Brown GL, Guckian JC, et al. A mechanism for the amelioration of hyperbaric
oxygen of experimental staphylococcal osteomyelitis in rabbits. J Infect Dis
42915, 1980.
Maxwell G, Meites H, Silverstein P Cost effectiveness of hyperbaric oxygen therapy
in burn care. Winter Symposium on Baromedicine, Aspen 1991 .
Merola L, Piscitelli F Considerations on the use of HBOT in the treatment of
burns. Ann Med Nav 83515, 1978.
Niccole MW, Thornton JW, Danet RT, et al. Hyperbaric oxygen in burn management
a controlled study. Surgery 82727, 1977.
Niu AKC, Yang C, Lee HC, et al. Burns treated with adjunctive hyperbaric oxygen
therapy a comparative study in humans. J Hyperbar Med 275, 1987.
Nylander G, Nordstrom H, Eriksson E Effects of hyperbaric oxygen on oedema formation
after a scald burn. Burns 10193, 1984.
Ogle CK, Alexander JW, Nagy E, et al. A long-term study and correlation of lymphocyte
and neutrophil function in the patient with burns. J Burn Care Rehab 112105,
1990.
Perrins DJD Failed attempt to limit tissue destruction in scalds of pig.s skin
with hyperbaric oxygen, in Wada J, Iwa T (eds) Proceedings of the Fourth International
Congress on Hyperbaric Medicine. Tokyo Igaku Shoin Ltd., 1970, p 381.
Ray CS, Green G, Cianci P Hyperbaric oxygen therapy in burn patients cost effective
adjuvant therapy (poster presentation). Undersea Biomed Res Suppl 1877, 1991.
Ross JC, Cianci PE Barotitis media resulting from hyperbaric oxygen therapy.
a retrospective study of 395 consecutive cases. Undersea Biomed Res Suppl 1702,
1990.
Saunders J, Fritz E, Ko F, et al. The effects of hyperbaric oxygen on dermal
ischemia following thermal injury. Proceedings of the American Burn Association
(New Orleans), 1989, p 58.
Stewart RJ, Yamaguchi KT, Cianci PE, et al. Effects of hyperbaric oxygen on adenosine
triphosphate in thermally injured skin. Surg Forum 3987, 1988.
Stewart RJ, Yamaguchi KT, Cianci PE, et al. Burn wound levels of ATP after exposure
to elevated levels of oxygen. Proceedings of the American Burn Association, (New
Orleans), 1989, p 67.
Tabor CG Hyperbaric oxygenation in the treatment of burns of less than forty
percent. Korean J Int Med, 1967.
Wada J, Ikeda T, Kamata K, et al. Oxygen hyperbaric treatment for carbon monoxide
poisoning and severe burn in coal mine (hokutanyubari) gas explosion. Igakunoaymi
(Japan) 553, 1965
Wada J, Ikeda K, Kagaya H, et al. Oxygen hyperbaric treatment and severe burn.
Jap Med J 132203, 1966.
Waisbren BA, Schultz D, Collentine G, et al. Hyperbaric oxygen in severe burns.
Burns 8176, 1982.
Wells CH, Hilton JG Effects of hyperbaric oxygen on post-burn plasma extravasation,
in Davis JC, Hunt TK (eds) Hyperbaric Oxygen Therapy. Bethesda Undersea Medical
Society, Inc., p 259, 1977.
Wiseman DH, Grossman AR Hyperbaric oxygen in the treatment of burns. Crit Care
Clin 2129, 1985.
Chronic Refractory Osteomyelitis
Osteomyelitis
represents an inflammatory process with a bacterial infection
involving bone. The disease involves ischemia as well as
infection, and it may be acute, subacute, or chronic. The
term "refractory osteomyelitis" refers
to failure to heal despite adequate surgical and antibiotic
therapy.
Clinicians use hyperbaric oxygen therapy
(HBOT) for the treatment of refractory, acute, or chronic
osteomyelitis. HBOT is purely adjunctive and must be used
with appropriate parenteral antibiotics (best determined
by bone culture), surgical debridement, nutritional support,
and reconstructive surgery.
In clinical practice, choosing
the best treatment for osteomyelitis presents physicians
with enormous challenges. Major therapies include antibiotics,
surgery, and adjunctive therapies, such as HBOT.
The results
of several open clinical trials indicate that adjunctive
hyperbaric oxygen therapy is useful in the treatment of chronic
osteomyelitis. To avoid the many variables of clinical osteomyelitis
and to objectively evaluate the effect of HBOT in the laboratory,
Mader used the Staphylococcus aureus osteomyelitis rabbit
model developed by Norden. Hyperbaric oxygen alone was as
effective as cephalothin in the treatment of experimental
S. aureus osteomyelitis.
To establish the mechanism of this
effectiveness of hyperbaric oxygen in osteomyelitis, further
studies were done. These studies provided evidence for the
following conclusions hyperbaric oxygen, when administered
under standard treatment conditions, was as effective as
cephalothin in the eradication of S. aureus from infected
bone; osteomyelitic bone in the experimental model has decreased
blood flow and a greatly decreased partial pressure of oxygen;
HBOT does not directly affect this strain of S. aureus; and
HBOT can restore intramedullary oxygen tensions to physiologic
or supraphysiologic levels, but this short exposure does
not acutely increase blood flow in osteomyelitic bone. One
mechanism for HBOT's effectiveness in S. aureus osteomyelitis
may be the increase of intramedullary oxygen to tensions
that maximize the efficiency of kill by phagocytes.
Increasing
the oxygen tension produces a direct lethal effect on strict
anaerobic organisms, and on some micro-aerophilic aerobic
organisms. During hyperbaric oxygen therapy, an increase
in oxygen tension leads to the increased concentration of
superoxide, both intracellularly and extracellularly. Increased
superoxide levels predispose to increased hydrogen peroxide
production (as well as higher output of other toxic oxygen
radicals). Anaerobic organisms are extremely sensitive to
these proliferating oxygen radicals because most lack the
superoxide-degrading enzyme, superoxide dismutase, and the
hydrogen peroxide-degrading enzyme, catalase.
Thus, an increase
in the oxygen tension with subsequent oxygen radical formation
proves lethal or bacteriostatic for anaerobic organisms.
Anaerobic organisms make up approximately 25 percent of the
isolates in non-hematogenous osteomyelitis. Hyperbaric oxygen
also augments the bactericidal action of the aminoglycoside
class of antibiotics. The major antibiotics in this drug
class include Gentamicin, Tobramycin, Amikacin, and Netilmicin.
The aminoglycosides lack good antibacterial activity under
low oxygen tensions. Low oxygen tensions are found in osteomyelitic
bone, and adjunctive hyperbaric oxygen increases tissue oxygen
tensions in infected tissue, which allows the aminoglycosides
to kill more effectively. Growth and killing studies of Pseudomonas
aeruginosa were done aerobically, anaerobically, and under
conditions which reproduce the hypoxic levels of infected
bone, with reduction of the killing of Pseudomonas aeruginosa
by tobramycin under hypoxic conditions. Adjunctive hyperbaric
oxygen may also potentiate the bactericidal effect of vancomycin.
Under low oxygen tensions, vancomycin, like the aminoglycosides,
does not kill micro-organisms as well as under as under normal
oxygen levels.
Oxygen is also important in wound healing.
When the environment of the fibroblast has an oxygen tension
of less than 10 mm Hg, the cell can divide, but it can no
longer synthesize collagen. It also cannot migrate to where
it is needed for healing. When the oxygen tension is increased,
the fibroblast can again carry out these wound healing functions.
The collagen produced by these cells forms a protective fibrous
matrix, and new capillaries grow into this matrix. Wound
healing is a dynamic process, and an adequate oxygen tension
is mandatory for this process to proceed to a successful
conclusion. HBOT provides oxygen to promote collagen production,
angiogenesis, and ultimately wound healing in the ischemic
or infected wound. Adequate wound healing is vital in the
treatment of osteomyelitis.
Once the bone and soft tissue
have been divided, whether by surgery or by infection, the
bone and wound must be protected by healing tissues. Bone
|